Abstract
Refractory status epilepticus (RSE) is a group of clinical manifestations that are caused by a variety of pathologies. Some cases of RSEs have no clear underlying cause, and these include some hereditary epilepsy syndromes in which the cause of RSE is unknown or has not yet been identified. Some cases of RSE occur in patients with pre-existing epilepsy, and these may represent epilepsy progression that occurs without disease-modifying interventions. In children, epilepsy syndromes manifest in a diversity of ways, including as RSE. Most cases of RSE involve multiple underlying causes, and most result from acute serious brain injury, such as hypoxic ischemic encephalopathy, autoimmune encephalitis, and infectious encephalitis. RSE is associated with different clinical features under different conditions, and different treatments are therefore required to treat each patient. Additionally, prognoses in RSE are related to its underlying cause.
In this chapter, we describe the manifestations and summarize the clinical features of RSE under a variety of conditions with the aim of improving the prevention and timely diagnosis of RSE.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, Laroche SM, Riviello JJ Jr, Shutter L, Sperling MR, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.
Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2005;76(4):534–9.
Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.
Wilder-Smith EP, Lim EC, Teoh HL, Sharma VK, Tan JJ, Chan BP, Ong BK. The NORSE (new-onset refractory status epilepticus) syndrome: defining a disease entity. Ann Acad Med Singap. 2005;34(7):417–20.
Kortvelyessy P, Lerche H, Weber Y. FIRES and NORSE are distinct entities. Epilepsia. 2012;53(7):1276.
Lyon G, Dodge PR, Adams RD. The acute encephalopathies of obscure origin in infants and children. Brain J Neurol. 1961;84:680–708.
DeLorenzo RJ, Hauser WA, Towne AR, Boggs JG, Pellock JM, Penberthy L, Garnett L, Fortner CA, Ko D. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology. 1996;46(4):1029–35.
Van Lierde I, Van Paesschen W, Dupont P, Maes A, Sciot R. De novo cryptogenic refractory multifocal febrile status epilepticus in the young adult: a review of six cases. Acta Neurol Belg. 2003;103(2):88–94.
Baxter P, Clarke A, Cross H, Harding B, Hicks E, Livingston J, Surtees R. Idiopathic catastrophic epileptic encephalopathy presenting with acute onset intractable status. Seizure. 2003;12(6):379–87.
Kramer U, Shorer Z, Ben-Zeev B, Lerman-Sagie T, Goldberg-Stern H, Lahat E. Severe refractory status epilepticus owing to presumed encephalitis. J Child Neurol. 2005;20(3):184–7.
Neuwirth M, Paraicz E, Liptai Z. Devastating epileptic encephalopathy-pseudoencephalitis: the new type of catastrophe epilepsy in our department. Ideggyogyaszati Szemle. 2008;61(11–12):391–6.
Sakuma H, Awaya Y, Shiomi M, Yamanouchi H, Takahashi Y, Saito Y, Sugai K, Sasaki M. Acute encephalitis with refractory, repetitive partial seizures (AERRPS): a peculiar form of childhood encephalitis. Acta Neurol Scand. 2010;121(4):251–6.
van Baalen A, Hausler M, Boor R, Rohr A, Sperner J, Kurlemann G, Panzer A, Stephani U, Kluger G. Febrile infection-related epilepsy syndrome (FIRES): a nonencephalitic encephalopathy in childhood. Epilepsia. 2010;51(7):1323–8.
Ismail FY, Kossoff EH. AERRPS, DESC, NORSE, FIRES: multi-labeling or distinct epileptic entities? Epilepsia. 2011;52(11):e185–9.
Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults-infectious or not? J Neurol Sci. 2009;277(1–2):26–31.
Milh M, Villeneuve N, Chapon F, Gavaret M, Girard N, Mancini J, Chabrol B, Boucraut J. New onset refractory convulsive status epilepticus associated with serum neuropil auto-antibodies in a school aged child. Brain Dev. 2011;33(8):687–91.
Gall CR, Jumma O, Mohanraj R. Five cases of new onset refractory status epilepticus (NORSE) syndrome: outcomes with early immunotherapy. Seizure. 2013;22(3):217–20.
Li J, Saldivar C, Maganti RK. Plasma exchange in cryptogenic new onset refractory status epilepticus. Seizure. 2013;22(1):70–3.
Jayalakshmi S, Vooturi S, Sahu S, Yada PK, Mohandas S. Causes and outcomes of new onset status epilepticus and predictors of refractoriness to therapy. J Clin Neurosci. 2016;26:89–94.
Gaspard N, Foreman BP, Alvarez V, Cabrera Kang C, Probasco JC, Jongeling AC, Meyers E, Espinera A, Haas KF, Schmitt SE, et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology. 2015;85(18):1604–13.
Sabharwal V, Ramsay E, Martinez R, Shumate R, Khan F, Dave H, Iwuchukwu I, McGrade H. Propofol-ketamine combination therapy for effective control of super-refractory status epilepticus. Epilepsy Behav. 2015;52(PT A):264–6.
Glaser CA, Gilliam S, Schnurr D, Forghani B, Honarmand S, Khetsuriani N, Fischer M, Cossen CK, Anderson LJ. In search of encephalitis etiologies: diagnostic challenges in the California encephalitis project, 1998-2000. Clin Infect Dis. 2003;36(6):731–42.
Hainsworth JB, Shishido A, Theeler BJ, Carroll CG, Fasano RE. Treatment responsive GABA(B)-receptor limbic encephalitis presenting as new-onset super-refractory status epilepticus (NORSE) in a deployed U.S. soldier. Epileptic Disord. 2014;16(4):486–93.
Bleck TP. Less common etiologies of status epilepticus. Epilepsy Curr. 2010;10(2):31–3.
Hurley K, Herron M, McDermott S, Farrell T, O'Riordan D. Squamous cell lung carcinoma presenting with refractory status epilepticus: a case report of paraneoplastic limbic encephalitis. Respir Care. 2015;60(8):e144–7.
Verma R, Raut TP, Giri P, Praharaj HN. New onset refractory status epilepticus (NORSE) as the heralding manifestation of herpes simplex encephalitis. BMJ Case Rep. 2013;2013
Illingworth MA, Hanrahan D, Anderson CE, O’Kane K, Anderson J, Casey M, de Sousa C, Cross JH, Wright S, Dale RC, et al. Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES). Dev Med Child Neurol. 2011;53(11):1053–7.
Jenssen S, Gracely EJ, Sperling MR. How long do most seizures last? A systematic comparison of seizures recorded in the epilepsy monitoring unit. Epilepsia. 2006;47(9):1499–503.
DeLorenzo RJ, Garnett LK, Towne AR, Waterhouse EJ, Boggs JG, Morton L, Choudhry MA, Barnes T, Ko D. Comparison of status epilepticus with prolonged seizure episodes lasting from 10 to 29 minutes. Epilepsia. 1999;40(2):164–9.
Mazarati AM, Wasterlain CG, Sankar R, Shin D. Self-sustaining status epilepticus after brief electrical stimulation of the perforant path. Brain Res. 1998;801(1–2):251–3.
Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol. 2011;10(1):99–108.
Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation. 2000;7(3):153–9.
Casamenti F, Prosperi C, Scali C, Giovannelli L, Colivicchi MA, Faussone-Pellegrini MS, Pepeu G. Interleukin-1beta activates forebrain glial cells and increases nitric oxide production and cortical glutamate and GABA release in vivo: implications for Alzheimer’s disease. Neuroscience. 1999;91(3):831–42.
Heida JG, Pittman QJ. Causal links between brain cytokines and experimental febrile convulsions in the rat. Epilepsia. 2005;46(12):1906–13.
Khawaja AM, DeWolfe JL, Miller DW, Szaflarski JP. New-onset refractory status epilepticus (NORSE)—the potential role for immunotherapy. Epilepsy Behav. 2015;47:17–23.
Puoti G, Elefante A, Saracino D, Capasso A, Cotrufo R, Anello CB. New-onset refractory status epilepticus mimicking herpes virus encephalitis. Case Rep Neurol. 2013;5(3):162–7.
Ferlisi M, Shorvon S. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135(Pt 8):2314–28.
Halawa EF, Draz I, Ahmed D, Shaheen HA. Predictors of outcome of convulsive status epilepticus among an Egyptian Pediatric tertiary hospital. J Child Neurol. 2015;30(13):1736–42.
Zeiler FA, Matuszczak M, Teitelbaum J, Kazina CJ, Gillman LM. Plasmapheresis for refractory status epilepticus, part I: a scoping systematic review of the adult literature. Seizure. 2016;43:14–22.
Pugin D, Foreman B, De Marchis GM, Fernandez A, Schmidt JM, Czeisler BM, Mayer SA, Agarwal S, Lesch C, Lantigua H, et al. Is pentobarbital safe and efficacious in the treatment of super-refractory status epilepticus: a cohort study. Crit Care. 2014;18(3):R103.
Lie IA, Hoggen I, Samsonsen C, Brodtkorb E. Treatment non-adherence as a trigger for status epilepticus: an observational, retrospective study based on therapeutic drug monitoring. Epilepsy Res. 2015;113:28–33.
Li Y, Tian L, Zeng T, Chen J, Chen L, Zhou D. Clinical features and outcome of super-refractory status epilepticus: a retrospective analysis in West China. Seizure. 2014;23(9):722–7.
Jayalakshmi S, Ruikar D, Vooturi S, Alladi S, Sahu S, Kaul S, Mohandas S. Determinants and predictors of outcome in super refractory status epilepticus—a developing country perspective. Epilepsy Res. 2014;108(9):1609–17.
Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA. Predictors of outcome in refractory status epilepticus. JAMA Neurol. 2013;70(1):72–7.
Young GB, Blume WT, Bolton CF, Warren KG. Anesthetic barbiturates in refractory status epilepticus. Can J Neurol Sci. 1980;7(4):291–2.
Nouailhat F, Levy-Alcover MA, Goulon M. Treatment of status epilepticus in the adult. Retrospective analysis of 192 cases treated in intensive care units. Rev Electroencephalogr Neurophysiol Clin. 1985;14(4):287–92.
Walker MC, Howard RS, Smith SJ, Miller DH, Shorvon SD, Hirsch NP. Diagnosis and treatment of status epilepticus on a neurological intensive care unit. QJM. 1996;89(12):913–20.
Neligan A, Shorvon SD. Frequency and prognosis of convulsive status epilepticus of different causes: a systematic review. Arch Neurol. 2010;67(8):931–40.
Lai A, Outin HD, Jabot J, Megarbane B, Gaudry S, Coudroy R, Louis G, Schneider F, Barbarot N, Roch A, et al. Functional outcome of prolonged refractory status epilepticus. Crit Care. 2015;19:199.
Ferlisi M, Hocker S, Grade M, Trinka E, Shorvon S. International steering committee of the StEp A: preliminary results of the global audit of treatment of refractory status epilepticus. Epilepsy Behav. 2015;49:318–24.
Alvarez V, Westover MB, Drislane FW, Dworetzky BA, Curley D, Lee JW, Rossetti AO. Evaluation of a clinical tool for early etiology identification in status epilepticus. Epilepsia. 2014;55(12):2059–68.
Sanchez Fernandez I, Abend NS, Agadi S, An S, Arya R, Brenton JN, Carpenter JL, Chapman KE, Gaillard WD, Glauser TA, et al. Time from convulsive status epilepticus onset to anticonvulsant administration in children. Neurology. 2015;84(23):2304–11.
Kamppi L, Mustonen H, Soinila S. Analysis of the delay components in the treatment of status epilepticus. Neurocrit Care. 2013;19(1):10–8.
Power KN, Flaatten H, Gilhus NE, Engelsen BA. Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome. Epilepsy Res. 2011;94(1–2):53–60.
Miyahara A, Saito Y, Sugai K, Nakagawa E, Sakuma H, Komaki H, Sasaki M. Reassessment of phenytoin for treatment of late stage progressive myoclonus epilepsy complicated with status epilepticus. Epilepsy Res. 2009;84(2–3):201–9.
Tassinari CA, Dravet C, Roger J, Cano JP, Gastaut H. Tonic status epilepticus precipitated by intravenous benzodiazepine in five patients with Lennox-Gastaut syndrome. Epilepsia. 1972;13(3):421–35.
Nobutoki T, Sugai K, Fukumizu M, Hanaoka S, Sasaki M. Continuous midazolam infusion for refractory nonconvulsive status epilepticus in children. No To Hattatsu. 2005;37(5):369–73.
Jayalakshmi S, Vooturi S, Chepuru R, Sahu S, Surath M. Aetiology and outcome of generalized convulsive status epilepticus in elderly. Seizure. 2015;29:104–8.
Kravljanac R, Djuric M, Jankovic B, Pekmezovic T. Etiology, clinical course and response to the treatment of status epilepticus in children: a 16-year single-center experience based on 602 episodes of status epilepticus. Eur J Paediatr Neurol. 2015;19(5):584–90.
Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde BW, Engel J, French J, Glauser TA, Mathern GW, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005-2009. Epilepsia. 2010;51(4):676–85.
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, Shorvon S, Lowenstein DH. A definition and classification of status epilepticus—report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515–23.
Coppola G, Plouin P, Chiron C, Robain O, Dulac O. Migrating partial seizures in infancy: a malignant disorder with developmental arrest. Epilepsia. 1995;36(10):1017–24.
Gerard F, Kaminska A, Plouin P, Echenne B, Dulac O. Focal seizures versus focal epilepsy in infancy: a challenging distinction. Epileptic Disord. 1999;1(2):135–9.
Okuda K, Yasuhara A, Kamei A, Araki A, Kitamura N, Kobayashi Y. Successful control with bromide of two patients with malignant migrating partial seizures in infancy. Brain Dev. 2000;22(1):56–9.
Gross-Tsur V, Ben-Zeev B, Shalev RS. Malignant migrating partial seizures in infancy. Pediatr Neurol. 2004;31(4):287–90.
Hmaimess G, Kadhim H, Nassogne MC, Bonnier C, van Rijckevorsel K. Levetiracetam in a neonate with malignant migrating partial seizures. Pediatr Neurol. 2006;34(1):55–9.
Coppola G. Malignant migrating partial seizures in infancy: an epilepsy syndrome of unknown etiology. Epilepsia. 2009;50(Suppl 5):49–51.
Carranza Rojo D, Hamiwka L, McMahon JM, Dibbens LM, Arsov T, Suls A, Stodberg T, Kelley K, Wirrell E, Appleton B, et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology. 2011;77(4):380–3.
Dhamija R, Wirrell E, Falcao G, Kirmani S, Wong-Kisiel LC. Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy. Pediatr Neurol. 2013;49(6):486–8.
Ohba C, Kato M, Takahashi S, Lerman-Sagie T, Lev D, Terashima H, Kubota M, Kawawaki H, Matsufuji M, Kojima Y, et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia. 2014;55(7):994–1000.
Poduri A, Chopra SS, Neilan EG, Elhosary PC, Kurian MA, Meyer E, Barry BJ, Khwaja OS, Salih MA, Stodberg T, et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012;53(8):e146–50.
Poduri A, Heinzen EL, Chitsazzadeh V, Lasorsa FM, Elhosary PC, LaCoursiere CM, Martin E, Yuskaitis CJ, Hill RS, Atabay KD, et al. SLC25A22 is a novel gene for migrating partial seizures in infancy. Ann Neurol. 2013;74(6):873–82.
Milh M, Falace A, Villeneuve N, Vanni N, Cacciagli P, Assereto S, Nabbout R, Benfenati F, Zara F, Chabrol B, et al. Novel compound heterozygous mutations in TBC1D24 cause familial malignant migrating partial seizures of infancy. Hum Mutat. 2013;34(6):869–72.
Saitsu H, Watanabe M, Akita T, Ohba C, Sugai K, Ong WP, Shiraishi H, Yuasa S, Matsumoto H, Beng KT, et al. Impaired neuronal KCC2 function by biallelic SLC12A5 mutations in migrating focal seizures and severe developmental delay. Sci Rep. 2016;6:30072.
Cilio MR, Bianchi R, Balestri M, Onofri A, Giovannini S, Di Capua M, Vigevano F. Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. Epilepsy Res. 2009;86(1):66–71.
Barcia G, Fleming MR, Deligniere A, Gazula VR, Brown MR, Langouet M, Chen H, Kronengold J, Abhyankar A, Cilio R, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44(11):1255–9.
McTague A, Appleton R, Avula S, Cross JH, King MD, Jacques TS, Bhate S, Cronin A, Curran A, Desurkar A, et al. Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum. Brain. 2013;136(Pt 5):1578–91.
Caraballo R, Pasteris MC, Fortini PS, Portuondo E. Epilepsy of infancy with migrating focal seizures: six patients treated with bromide. Seizure. 2014;23(10):899–902.
Bearden D, Strong A, Ehnot J, DiGiovine M, Dlugos D, Goldberg EM. Targeted treatment of migrating partial seizures of infancy with quinidine. Ann Neurol. 2014;76(3):457–61.
Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014;75(4):581–90.
Caraballo R, Noli D, Cachia P. Epilepsy of infancy with migrating focal seizures: three patients treated with the ketogenic diet. Epileptic Disord. 2015;17(2):194–7.
Shein SL, Reynolds TQ, Gedela S, Kochanek PM, Bell MJ. Therapeutic hypothermia for refractory status epilepticus in a child with malignant migrating partial seizures of infancy and SCN1A mutation: a case report. Ther Hypothermia Temp Manag. 2012;2(3):144–9.
Connolly MB. Dravet syndrome: diagnosis and long-term course. Can J Neurol Sci. 2016;43(Suppl 3):S3–8.
Shmuely S, Sisodiya SM, Gunning WB, Sander JW, Thijs RD. Mortality in Dravet syndrome: a review. Epilepsy Behav. 2016;64(Pt A):69–74.
Marini C, Scheffer IE, Nabbout R, Suls A, De Jonghe P, Zara F, Guerrini R. The genetics of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):24–9.
Depienne C, Bouteiller D, Keren B, Cheuret E, Poirier K, Trouillard O, Benyahia B, Quelin C, Carpentier W, Julia S, et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet. 2009;5(2):e1000381.
Shi X, Yasumoto S, Nakagawa E, Fukasawa T, Uchiya S, Hirose S. Missense mutation of the sodium channel gene SCN2A causes Dravet syndrome. Brain Dev. 2009;31(10):758–62.
Ishii A, Kanaumi T, Sohda M, Misumi Y, Zhang B, Kakinuma N, Haga Y, Watanabe K, Takeda S, Okada M, et al. Association of nonsense mutation in GABRG2 with abnormal trafficking of GABAA receptors in severe epilepsy. Epilepsy Res. 2014;108(3):420–32.
Carvill GL, Weckhuysen S, McMahon JM, Hartmann C, Moller RS, Hjalgrim H, Cook J, Geraghty E, O'Roak BJ, Petrou S, et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology. 2014;82(14):1245–53.
Tanabe T, Awaya Y, Matsuishi T, Iyoda K, Nagai T, Kurihara M, Yamamoto K, Minagawa K, Maekawa K. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)—a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629–35.
Berio A, Piazzi A. Activity of drugs and components of natural origin in the severe myoclonic epilepsy of infancy (Dravet syndrome). Cent Nerv Syst Agents Med Chem. 2015;15(2):95–8.
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–8.
Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627–33.
Shi XY, Tomonoh Y, Wang WZ, Ishii A, Higurashi N, Kurahashi H, Kaneko S, Hirose S. Efficacy of antiepileptic drugs for the treatment of Dravet syndrome with different genotypes. Brain Dev. 2016;38(1):40–6.
Specchio N, Balestri M, Trivisano M, Japaridze N, Striano P, Carotenuto A, Cappelletti S, Specchio LM, Fusco L, Vigevano F. Electroencephalographic features in dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27(4):439–44.
Dravet C, Bureau M, Oguni H, Fukuyama Y, Cokar O. Severe myoclonic epilepsy in infancy: Dravet syndrome. Adv Neurol. 2005;95:71–102.
Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet syndrome. Paediatr Drugs. 2016;18(3):197–208.
Dressler A, Trimmel-Schwahofer P, Reithofer E, Muhlebner A, Groppel G, Reiter-Fink E, Benninger F, Grassl R, Feucht M. Efficacy and tolerability of the ketogenic diet in Dravet syndrome—comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–9.
Dlouhy BJ, Miller B, Jeong A, Bertrand ME, Limbrick DD Jr, Smyth MD. Palliative epilepsy surgery in Dravet syndrome-case series and review of the literature. Child’s Nerv Syst. 2016;32(9):1703–8.
Ragona F, Granata T, Dalla Bernardina B, Offredi F, Darra F, Battaglia D, Morbi M, Brazzo D, Cappelletti S, Chieffo D, et al. Cognitive development in Dravet syndrome: a retrospective, multicenter study of 26 patients. Epilepsia. 2011;52(2):386–92.
Rilstone JJ, Coelho FM, Minassian BA, Andrade DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53(8):1421–8.
Verbeek NE, Wassenaar M, van Campen JS, Sonsma A, Gunning B, Knoers N, Lindhout D, Jansen FE, Leijten F, Brilstra EH, et al. Seizure precipitants in Dravet syndrome: what events and activities are specifically provocative compared with other epilepsies? Epilepsy Behav. 2015;47:39–44.
Okumura A, Uematsu M, Imataka G, Tanaka M, Okanishi T, Kubota T, Sudo A, Tohyama J, Tsuji M, Ohmori I, et al. Acute encephalopathy in children with Dravet syndrome. Epilepsia. 2012;53(1):79–86.
Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135(Pt 8):2329–36.
Sakauchi M, Oguni H, Kato I, Osawa M, Hirose S, Kaneko S, Takahashi Y, Takayama R, Fujiwara T. Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 2011;52(Suppl 2):50–4.
Gallentine WB, Mikati MA. Genetic generalized epilepsies. J Clin Neurophysiol. 2012;29(5):408–19.
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30(4):389–99.
Blume WT, Luders HO, Mizrahi E, Tassinari C, van Emde BW, Engel J Jr. Glossary of descriptive terminology for ictal semiology: report of the ILAE task force on classification and terminology. Epilepsia. 2001;42(9):1212–8.
Engel J Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. Epilepsia. 2001;42(6):796–803.
Nordli DR Jr. Idiopathic generalized epilepsies recognized by the international League against epilepsy. Epilepsia. 2005;46(Suppl 9):48–56.
Asadi-Pooya AA, Emami M, Sperling MR. A clinical study of syndromes of idiopathic (genetic) generalized epilepsy. J Neurol Sci. 2013;324(1–2):113–7.
Panayiotopoulos CP. The new ILAE report on terminology and concepts for the organization of epilepsies: critical review and contribution. Epilepsia. 2012;53(3):399–404.
Jallon P, Latour P. Epidemiology of idiopathic generalized epilepsies. Epilepsia. 2005;46(Suppl 9):10–4.
Shorvon S, Walker M. Status epilepticus in idiopathic generalized epilepsy. Epilepsia. 2005;46(Suppl 9):73–9.
Genton P, Ferlazzo E, Thomas P. Absence status epilepsy: delineation of a distinct idiopathic generalized epilepsy syndrome. Epilepsia. 2008;49(4):642–9.
Thomas P, Valton L, Genton P. Absence and myoclonic status epilepticus precipitated by antiepileptic drugs in idiopathic generalized epilepsy. Brain. 2006;129(Pt 5):1281–92.
Wheless JW. Acute management of seizures in the syndromes of idiopathic generalized epilepsies. Epilepsia. 2003;44(Suppl 2):22–6.
Agathonikou A, Panayiotopoulos CP, Giannakodimos S, Koutroumanidis M. Typical absence status in adults: diagnostic and syndromic considerations. Epilepsia. 1998;39(12):1265–76.
Dziewas R, Kellinghaus C, Ludemann P. Nonconvulsion status epilepticus in patients with juvenile myoclonic epilepsy: types and frequencies. Seizure. 2002;11(5):335–9.
Shirasaka Y. Lack of neuronal damage in atypical absence status epilepticus. Epilepsia. 2002;43(12):1498–501.
Wong M, Wozniak DF, Yamada KA. An animal model of generalized nonconvulsive status epilepticus: immediate characteristics and long-term effects. Exp Neurol. 2003;183(1):87–99.
Badhwar A, Siren A, Andermann E, Andermann F. Myoclonic status epilepticus: video presentation. Mov Disord. 2002;17(2):409–11.
Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia. 1994;35(2):285–96.
Sheth RD, Gidal BE. Intravenous valproic acid for myoclonic status epilepticus. Neurology. 2000;54(5):1201.
Bilo L, Pappata S, De Simone R, Meo R. The syndrome of absence status epilepsy: review of the literature. Epilepsy Res Treat. 2014;2014:624309.
Venkataraman V, Wheless JW. Safety of rapid intravenous infusion of valproate loading doses in epilepsy patients. Epilepsy Res. 1999;35(2):147–53.
Zaki SA, Verma DK, Tayde P. Panayiotopoulos syndrome in a child masquerading as septic shock. Indian J Crit Care Med. 2016;20(6):361–3.
Panayiotopoulos CP, Michael M, Sanders S, Valeta T, Koutroumanidis M. Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. Brain. 2008;131(Pt 9):2264–86.
Degerliyurt A, Teber S, Bektas O, Senkon G. Panayiotopoulos syndrome: a case series from Turkey. Epilepsy Behav. 2014;36:24–32.
Oguni H, Hayashi K, Imai K, Hirano Y, Mutoh A, Osawa M. Study on the early-onset variant of benign childhood epilepsy with occipital paroxysms otherwise described as early-onset benign occipital seizure susceptibility syndrome. Epilepsia. 1999;40(7):1020–30.
Kivity S, Ephraim T, Weitz R, Tamir A. Childhood epilepsy with occipital paroxysms: clinical variants in 134 patients. Epilepsia. 2000;41(12):1522–33.
Lada C, Skiadas K, Theodorou V, Loli N, Covanis A. A study of 43 patients with panayiotopoulos syndrome, a common and benign childhood seizure susceptibility. Epilepsia. 2003;44(1):81–8.
Ohtsu M, Oguni H, Hayashi K, Funatsuka M, Imai K, Osawa M. EEG in children with early-onset benign occipital seizure susceptibility syndrome: Panayiotopoulos syndrome. Epilepsia. 2003;44(3):435–42.
Ferrie CD, Caraballo R, Covanis A, Demirbilek V, Dervent A, Fejerman N, Fusco L, Grunewald RA, Kanazawa O, Koutroumanidis M, et al. Autonomic status epilepticus in Panayiotopoulos syndrome and other childhood and adult epilepsies: a consensus view. Epilepsia. 2007;48(6):1165–72.
Panayiotopoulos CP. Autonomic seizures and autonomic status epilepticus peculiar to childhood: diagnosis and management. Epilepsy Behav. 2004;5(3):286–95.
Ferrie C, Caraballo R, Covanis A, Demirbilek V, Dervent A, Kivity S, Koutroumanidis M, Martinovic Z, Oguni H, Verrotti A, et al. Panayiotopoulos syndrome: a consensus view. Dev Med Child Neurol. 2006;48(3):236–40.
Chahine LM, Mikati MA. Benign pediatric localization-related epilepsies. Part I. Syndromes in infancy. Epileptic Disord. 2006;8(3):169–83.
Caraballo RH, Pasteris MC, Portuondo E, Fortini PS. Panayiotopoulos syndrome and diffuse paroxysms as the first EEG manifestation at clinical onset: a study of nine patients. Epileptic Disord. 2015;17(2):143–9.
Kikumoto K, Yoshinaga H, Oka M, Ito M, Endoh F, Akiyama T, Ohtsuka Y. EEG and seizure exacerbation induced by carbamazepine in Panayiotopoulos syndrome. Epileptic Disord. 2006;8(1):53–6.
Garcia C, Rubio G. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. Epilepsy Res. 2009;85(2–3):318–20.
Verrotti A, Sebastiani M, Giordano L, Striano P, Belcastro V, Franzoni E, Parisi P, Pruna D, Spalice A, Vignoli A, et al. Panayiotopoulos syndrome with convulsive status epilepticus at the onset: a long-term study. Seizure. 2014;23(9):728–31.
Kanemura H, Sano F, Ohyama T, Aoyagi K, Sugita K, Aihara M. Sequential prefrontal lobe volume changes and cognitive dysfunctions in children with Panayiotopoulos syndrome presenting with status epilepticus. Epilepsy Res. 2015;112:122–9.
Neubauer BA, Hahn A, Doose H, Tuxhorn I. Myoclonic-astatic epilepsy of early childhood--definition, course, nosography, and genetics. Adv Neurol. 2005;95:147–55.
Scheffer IE, Wallace R, Mulley JC, Berkovic SF. Clinical and molecular genetics of myoclonic-astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain Dev. 2001;23(7):732–5.
Wallace RH, Scheffer IE, Parasivam G, Barnett S, Wallace GB, Sutherland GR, Berkovic SF, Mulley JC. Generalized epilepsy with febrile seizures plus: mutation of the sodium channel subunit SCN1B. Neurology. 2002;58(9):1426–9.
Mullen SA, Marini C, Suls A, Mei D, Della Giustina E, Buti D, Arsov T, Damiano J, Lawrence K, De Jonghe P, et al. Glucose transporter 1 deficiency as a treatable cause of myoclonic astatic epilepsy. Arch Neurol. 2011;68(9):1152–5.
Carvill GL, Heavin SB, Yendle SC, McMahon JM, O'Roak BJ, Cook J, Khan A, Dorschner MO, Weaver M, Calvert S, et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet. 2013;45(7):825–30.
Carvill GL, McMahon JM, Schneider A, Zemel M, Myers CT, Saykally J, Nguyen J, Robbiano A, Zara F, Specchio N, et al. Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet. 2015;96(5):808–15.
Oguni H, Fukuyama Y, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, Osawa M. Myoclonic-astatic epilepsy of early childhood—clinical and EEG analysis of myoclonic-astatic seizures, and discussions on the nosology of the syndrome. Brain Dev. 2001;23(7):757–64.
Kilaru S, Bergqvist AG. Current treatment of myoclonic astatic epilepsy: clinical experience at the Children’s Hospital of Philadelphia. Epilepsia. 2007;48(9):1703–7.
Kaminska A, Oguni H. Lennox-Gastaut syndrome and epilepsy with myoclonic-astatic seizures. Handb Clin Neurol. 2013;111:641–52.
Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol. 2010;52(11):988–93.
Oguni H, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, Osawa M. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics. 2002;33(3):122–32.
Doose H, Gerken H, Leonhardt R, Volzke E, Volz C. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie. 1970;2(1):59–78.
Deng J, Zhang YH, Liu XY, Yang ZX, Xiong H, Wang S, Bao XH, Jiang YW, Qin J, Lin Q, et al. Electroclinical features of myoclonic-atonic epilepsy. Zhonghua er ke za zhi. 2011;49(8):577–82.
Caraballo RH, Chamorro N, Darra F, Fortini S, Arroyo H. Epilepsy with myoclonic atonic seizures: an electroclinical study of 69 patients. Pediatr Neurol. 2013;48(5):355–62.
Trivisano M, Specchio N, Cappelletti S, Di Ciommo V, Claps D, Specchio LM, Vigevano F, Fusco L. Myoclonic astatic epilepsy: an age-dependent epileptic syndrome with favorable seizure outcome but variable cognitive evolution. Epilepsy Res. 2011;97(1–2):133–41.
Grande-Martin A, Pardal-Fernandez JM, Carrascosa-Romero MC, De Cabo C. Tonic seizure status epilepticus triggered by valproate in a child with Doose syndrome. Neuropediatrics. 2016;47(3):187–9.
Oguni H, Hayashi K, Imai K, Funatsuka M, Sakauchi M, Shirakawa S, Osawa M. Idiopathic myoclonic-astatic epilepsy of early childhood—nosology based on electrophysiologic and long-term follow-up study of patients. Adv Neurol. 2005;95:157–74.
Kalviainen R. Progressive myoclonus epilepsies. Semin Neurol. 2015;35(3):293–9.
Striano P, Zara F, Turnbull J, Girard JM, Ackerley CA, Cervasio M, De Rosa G, Del Basso-De Caro ML, Striano S, Minassian BA. Typical progression of myoclonic epilepsy of the Lafora type: a case report. Nat Clin Pract Neurol. 2008;4(2):106–11.
Frei KP, Schiffmann R. Myoclonus in Gaucher disease. Adv Neurol. 2002;89:41–8.
Hayashi M, Kumada S, Shioda K, Fukatsu R. Neuropathological analysis of the brainstem and cerebral cortex lesions on epileptogenesis in hereditary dentatorubral-pallidoluysian atrophy. Brain Dev. 2007;29(8):473–81.
Oguz Akarsu E, Tekturk P, Yapici Z, Tepgec F, Uyguner ZO, Baykan B. Eyelid myoclonic status epilepticus: a rare phenotype in spinal muscular atrophy with progressive myoclonic epilepsy associated with ASAH1 gene mutation. Seizure. 2016;42:49–51.
Hashmi M, Saleem F, Mustafa MS, Sheerani M, Ehtesham Z, Siddiqui K. Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease. BMJ Case Rep. 2010;2010
Lopez-Meza EG, Cerda-Tellez F, Alanis-Guevara IM, Fernandez Gonzalez-Aragon MC, Ruano-Calderon LA. Non-convulsive epileptic status associated with Lafora disease: two case reports. Rev Neurol. 2003;37(10):945–7.
Caraballo RH, Valenzuela GR, Armeno M, Fortini S, Mestre G, Cresta A. The ketogenic diet in two paediatric patients with refractory myoclonic status epilepticus. Epileptic Disord. 2015;17(4):491–5.
Chen J, Yang Z, Liu X, Ji T, Fu N, Wu Y, et al. [Efficacy of methylprednisolone therapy for electrical status epilepticus during sleep in children]. Zhonghua Er Ke Za Zhi. 2014;52(9):678–82. [Article in Chinese].
Patry G, Lyagoubi S, Tassinari CA. Subclinical “electrical status epilepticus” induced by sleep in children. A clinical and electroencephalographic study of six cases. Arch Neurol. 1971;24(3):242–52.
Galanopoulou AS, Bojko A, Lado F, Moshe SL. The spectrum of neuropsychiatric abnormalities associated with electrical status epilepticus in sleep. Brain Dev. 2000;22(5):279–95.
Doose H, Baier WK. Benign partial epilepsy and related conditions: multifactorial pathogenesis with hereditary impairment of brain maturation. Eur J Pediatr. 1989;149(3):152–8.
Aicardi J, Chevrie JJ. Atypical benign partial epilepsy of childhood. Dev Med Child Neurol. 1982;24(3):281–92.
Kramer U. Atypical presentations of benign childhood epilepsy with centrotemporal spikes: a review. J Child Neurol. 2008;23(7):785–90.
Su TF, Xu SQ, Chen L. Efficacy of levetiracetam combined with short-term clonazepam in treatment of electrical status epilepticus during sleep in children with benign childhood epilepsy with centrotemporal spikes. Zhongguo dang dai er ke za zhi. 2014;16(8):829–33.
Doose H, Hahn A, Neubauer BA, Pistohl J, Stephani U. Atypical “benign” partial epilepsy of childhood or pseudo-lennox syndrome. Part II: family study. Neuropediatrics. 2001;32(1):9–13.
Cerminara C, Montanaro ML, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology. 2004;63(2):373–5.
Gelisse P, Crespel A, Genton P, Baldy-Moulinier M. Dramatic effect of levetiracetam on epileptic negative myoclonus. Acta Neurol Scand. 2003;107(4):302–3.
Capovilla G, Beccaria F, Veggiotti P, Rubboli G, Meletti S, Tassinari CA. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol. 1999;14(6):395–400.
Parmeggiani L, Seri S, Bonanni P, Guerrini R. Electrophysiological characterization of spontaneous and carbamazepine-induced epileptic negative myoclonus in benign childhood epilepsy with centro-temporal spikes. Clin Neurophysiol. 2004;115(1):50–8.
Kramer U, Ben-Zeev B, Harel S, Kivity S. Transient oromotor deficits in children with benign childhood epilepsy with central temporal spikes. Epilepsia. 2001;42(5):616–20.
Hamano S, Mochizuki M, Morikawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure. 2002;11(3):201–4.
Tassinari CA, Rubboli G, Volpi L, Meletti S, d'Orsi G, Franca M, Sabetta AR, Riguzzi P, Gardella E, Zaniboni A, et al. Encephalopathy with electrical status epilepticus during slow sleep or ESES syndrome including the acquired aphasia. Clin Neurophysiol. 2000;111(Suppl 2):S94–s102.
Herguner MO, Incecik F, Altunbasak S, Kiris N. Clinical characteristics of 10 patients with continuous spikes and waves during slow sleep syndrome. Pediatr Neurol. 2008;38(6):411–4.
Buzatu M, Bulteau C, Altuzarra C, Dulac O, Van Bogaert P. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia. 2009;50(Suppl 7):68–72.
Praline J, Hommet C, Barthez MA, Brault F, Perrier D, Passage GD, Lucas B, Bonnard J, Billard C, Toffol BD, et al. Outcome at adulthood of the continuous spike-waves during slow sleep and Landau-Kleffner syndromes. Epilepsia. 2003;44(11):1434–40.
Scheltens-de Boer M. Guidelines for EEG in encephalopathy related to ESES/CSWS in children. Epilepsia. 2009;50(Suppl 7):13–7.
Seri S, Thai JN, Brazzo D, Pisani F, Cerquiglini A. Neurophysiology of CSWS-associated cognitive dysfunction. Epilepsia. 2009;50(Suppl 7):33–6.
Downes M, Greenaway R, Clark M, Helen Cross J, Jolleff N, Harkness W, Kaliakatsos M, Boyd S, White S, Neville BG. Outcome following multiple subpial transection in Landau-Kleffner syndrome and related regression. Epilepsia. 2015;56(11):1760–6.
Arts WF, Aarsen FK, Scheltens-de Boer M, Catsman-Berrevoets CE. Landau-Kleffner syndrome and CSWS syndrome: treatment with intravenous immunoglobulins. Epilepsia. 2009;50(Suppl 7):55–8.
Tsuru T, Mori M, Mizuguchi M, Momoi MY. Effects of high-dose intravenous corticosteroid therapy in Landau-Kleffner syndrome. Pediatr Neurol. 2000;22(2):145–7.
Sinclair DB, Snyder TJ. Corticosteroids for the treatment of Landau-kleffner syndrome and continuous spike-wave discharge during sleep. Pediatr Neurol. 2005;32(5):300–6.
Okuyaz C, Aydin K, Gucuyener K, Serdaroglu A. Treatment of electrical status epilepticus during slow-wave sleep with high-dose corticosteroid. Pediatr Neurol. 2005;32(1):64–7.
Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, Genton P, Guerrini R, Kluger G, Pellock JM, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82–93.
Al-Banji MH, Zahr DK, Jan MM. Lennox-Gastaut syndrome. Management update. Neurosciences. 2015;20(3):207–12.
Hoffmann-Riem M, Diener W, Benninger C, Rating D, Unnebrink K, Stephani U, Ernst HP, Korinthenberg R. Nonconvulsive status epilepticus—a possible cause of mental retardation in patients with Lennox-Gastaut syndrome. Neuropediatrics. 2000;31(4):169–74.
Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J Clin Neurophysiol. 2003;20(6):426–41.
Gibbs FA, Davis H, Lennox WG. The electroencephalogram in epilepsy and in conditions of impaired consciousness. Arch Neural Psychiatry.1935;34:1133–48.
Gastraut H, Roger J, Soulayrol R, Tassinari CA, Regis H, Dravet C, Bernard R, Pinsard N, Saint-Jean M. Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as “petit mal variant”) or Lennox syndrome. Epilepsia. 1966;7(2):139–79.
Gastaut H. The Lennox-Gastaut syndrome: comments on the syndrome's terminology and nosological position amongst the secondary generalized epilepsies of childhood. Electroencephalogr Clin Neurophysiol Suppl. 1982;35:71–84.
Kumar A, Paliwal VK, Agarwal V, Neyaz Z, Lal H, Goel G. Relationship of Lennox-Gastaut syndrome with perinatal event: a cross-sectional study. J Pediatr Neurosci. 2015;10(2):98–102.
Chevrie JJ, Aicardi J. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases. Epilepsia. 1972;13(2):259–71.
Crumrine PK. Management of seizures in Lennox-Gastaut syndrome. Paediatr Drugs. 2011;13(2):107–18.
Crumrine PK. Lennox-Gastaut syndrome. J Child Neurol. 2002;17(Suppl 1):S70–5.
Bittencourt PR, Richens A. Anticonvulsant-induced status epilepticus in Lennox-Gastaut syndrome. Epilepsia. 1981;22(1):129–34.
Markand ON. Slow spike-wave activity in EEG and associated clinical features: often called ‘Lennox’ or “Lennox-Gastaut” syndrome. Neurology. 1977;27(8):746–57.
Youn YA, Kim JH, Yum SK, Moon CJ, Lee IG, Sung IK. The hospital outcomes compared between the early and late hypothermia-treated groups in neonates. J Matern Fetal Neonatal Med. 2016;29(14):2288–92.
Simpson RK Jr, Goodman JC, Rouah E, Caraway N, Baskin DS. Late neuropathological consequences of strangulation. Resuscitation. 1987;15(3):171–85.
Jumao-as A, Brenner RP. Myoclonic status epilepticus: a clinical and electroencephalographic study. Neurology. 1990;40(8):1199–202.
Sirsi D, Nangia S, LaMothe J, Kosofsky BE, Solomon GE. Successful management of refractory neonatal seizures with midazolam. J Child Neurol. 2008;23(6):706–9.
Sutter R, Marsch S, Fuhr P, Ruegg S. Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia. 2013;54(3):502–11.
Rittenberger JC, Popescu A, Brenner RP, Guyette FX, Callaway CW. Frequency and timing of nonconvulsive status epilepticus in comatose post-cardiac arrest subjects treated with hypothermia. Neurocrit Care. 2012;16(1):114–22.
Legriel S, Hilly-Ginoux J, Resche-Rigon M, Merceron S, Pinoteau J, Henry-Lagarrigue M, Bruneel F, Nguyen A, Guezennec P, Troche G, et al. Prognostic value of electrographic postanoxic status epilepticus in comatose cardiac-arrest survivors in the therapeutic hypothermia era. Resuscitation. 2013;84(3):343–50.
Krumholz A, Stern BJ, Weiss HD. Outcome from coma after cardiopulmonary resuscitation: relation to seizures and myoclonus. Neurology. 1988;38(3):401–5.
Buttram SD, Au AK, Koch J, Lidsky K, McBain K, O'Brien N, Zielinski BA, Bell MJ. Feasibility study evaluating therapeutic hypothermia for refractory status epilepticus in children. Ther Hypothermia Temp Manag. 2015;5(4):198–202.
Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344–9.
Laptook AR, Corbett RJ, Nguyen HT, Peterson J, Nunnally RL. Alterations in cerebral blood flow and phosphorylated metabolites in piglets during and after partial ischemia. Pediatr Res. 1988;23(2):206–11.
Vannucci RC, Yager JY, Vannucci SJ. Cerebral glucose and energy utilization during the evolution of hypoxic-ischemic brain damage in the immature rat. J Cereb Blood Flow Metab. 1994;14(2):279–88.
Younkin DP, Wagerle LC, Chance B, Maria J, Delivoria-Papadopoulos M. 31P–-NMR studies of cerebral metabolic changes during graded hypoxia in newborn lambs. J Appl Physiol. 1987;62(4):1569–74.
Hope PL, Costello AM, Cady EB, Delpy DT, Tofts PS, Chu A, Hamilton PA, Reynolds EO, Wilkie DR. Cerebral energy metabolism studied with phosphorus NMR spectroscopy in normal and birth-asphyxiated infants. Lancet. 1984;2(8399):366–70.
Johnston MV. Excitotoxicity in neonatal hypoxia. Ment Retard Dev Disabil Res Rev. 2001;7(4):229–34.
Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci. 2000;20(24):9235–41.
Cataltepe O, Towfighi J, Vannucci RC. Cerebrospinal fluid concentrations of glutamate and GABA during perinatal cerebral hypoxia-ischemia and seizures. Brain Res. 1996;709(2):326–30.
Zanelli SA, Rajasekaran K, Grosenbaugh DK, Kapur J. Increased excitability and excitatory synaptic transmission during in vitro ischemia in the neonatal mouse hippocampus. Neuroscience. 2015;310:279–89.
Kristian T, Siesjo BK. Calcium in ischemic cell death. Stroke. 1998;29(3):705–18.
Vannucci RC, Brucklacher RM, Vannucci SJ. Intracellular calcium accumulation during the evolution of hypoxic-ischemic brain damage in the immature rat. Brain Res Dev Brain Res. 2001;126(1):117–20.
Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab. 2001;21(1):2–14.
Fullerton HJ, Ditelberg JS, Chen SF, Sarco DP, Chan PH, Epstein CJ, Ferriero DM. Copper/zinc superoxide dismutase transgenic brain accumulates hydrogen peroxide after perinatal hypoxia ischemia. Ann Neurol. 1998;44(3):357–64.
Nelson KB, Willoughby RE. Infection, inflammation and the risk of cerebral palsy. Curr Opin Neurol. 2000;13(2):133–9.
Yoon BH, Jun JK, Romero R, Park KH, Gomez R, Choi JH, Kim IO. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol. 1997;177(1):19–26.
Eklind S, Mallard C, Leverin AL, Gilland E, Blomgren K, Mattsby-Baltzer I, Hagberg H. Bacterial endotoxin sensitizes the immature brain to hypoxic—ischaemic injury. Eur J Neurosci. 2001;13(6):1101–6.
Xu ZH, Wang Y, Tao AF, Yu J, Wang XY, Zu YY, Zhang SH, Chen Z. Interleukin-1 receptor is a target for adjunctive control of diazepam-refractory status epilepticus in mice. Neuroscience. 2016;328:22–9.
Snyder BD, Hauser WA, Loewenson RB, Leppik IE, Ramirez-Lassepas M, Gumnit RJ. Neurologic prognosis after cardiopulmonary arrest: III. Seizure activity. Neurology. 1980;30(12):1292–7.
Morris HR, Howard RS, Brown P. Early myoclonic status and outcome after cardiorespiratory arrest. J Neurol Neurosurg Psychiatry. 1998;64(2):267–8.
Arnoldus EP, Lammers GJ. Postanoxic coma: good recovery despite myoclonus status. Ann Neurol. 1995;38(4):697–8.
Hui AC, Cheng C, Lam A, Mok V, Joynt GM. Prognosis following postanoxic myoclonus status epilepticus. Eur Neurol. 2005;54(1):10–3.
McGinn KA, Bishop L, Sarwal A. Use of ketamine in barbiturate coma for status epilepticus. Clin Neuropharmacol. 2016;39(1):62–5.
Anderson CA, Arciniegas DB. Cognitive sequelae of hypoxic-ischemic brain injury: a review. NeuroRehabilitation. 2010;26(1):47–63.
Thomke F, Marx JJ, Sauer O, Hundsberger T, Hagele S, Wiechelt J, Weilemann SL. Observations on comatose survivors of cardiopulmonary resuscitation with generalized myoclonus. BMC Neurol. 2005;5:14.
Akman CI, Abou Khaled KJ, Segal E, Micic V, Riviello JJ. Generalized periodic epileptiform discharges in critically ill children: clinical features, and outcome. Epilepsy Res. 2013;106(3):378–85.
Pandian JD, Cascino GD, So EL, Manno E, Fulgham JR. Digital video-electroencephalographic monitoring in the neurological-neurosurgical intensive care unit: clinical features and outcome. Arch Neurol. 2004;61(7):1090–4.
Drislane FW, Lopez MR, Blum AS, Schomer DL. Detection and treatment of refractory status epilepticus in the intensive care unit. J Clin Neurophysiol. 2008;25(4):181–6.
Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4(6):757–60.
Mader EC Jr, Villemarette-Pittman NR, Kashirny SV, Santana-Gould L, Olejniczak PW. Typical spike-and-wave activity in hypoxic-ischemic brain injury and its implications for classifying nonconvulsive status epilepticus. Clin Med Insights Case Rep. 2012;5:99–106.
Suppiej A, Cappellari A, Cogo PE. Prognostic role of somatosensory and auditory evoked potentials in paediatric hypoxic-ischemic encephalopathy managed with hypothermia: an illustrative case. Clin Neurophysiol. 2009;39(2):101–5.
Lemiale V, Huet O, Vigue B, Mathonnet A, Spaulding C, Mira JP, Carli P, Duranteau J, Cariou A. Changes in cerebral blood flow and oxygen extraction during post-resuscitation syndrome. Resuscitation. 2008;76(1):17–24.
Polderman KH, Herold I. Therapeutic hypothermia and controlled normothermia in the intensive care unit: practical considerations, side effects, and cooling methods. Crit Care Med. 2009;37(3):1101–20.
Atkins CM, Truettner JS, Lotocki G, Sanchez-Molano J, Kang Y, Alonso OF, Sick TJ, Dietrich WD, Bramlett HM. Post-traumatic seizure susceptibility is attenuated by hypothermia therapy. Eur J Neurosci. 2010;32(11):1912–20.
D'Ambrosio R, Eastman CL, Darvas F, Fender JS, Verley DR, Farin FM, Wilkerson HW, Temkin NR, Miller JW, Ojemann J, et al. Mild passive focal cooling prevents epileptic seizures after head injury in rats. Ann Neurol. 2013;73(2):199–209.
Schmitt FC, Buchheim K, Meierkord H, Holtkamp M. Anticonvulsant properties of hypothermia in experimental status epilepticus. Neurobiol Dis. 2006;23(3):689–96.
Yu L, Zhou Y, Chen W, Wang Y. Mild hypothermia pretreatment protects against pilocarpine-induced status epilepticus and neuronalapoptosis in immature rats. Neuropathology. 2011;31(2):144–51.
Wang Y, Liu PP, Li LY, Zhang HM, Li T. Hypothermia reduces brain edema, spontaneous recurrent seizure attack, and learning memory deficits in the kainic acid treated rats. CNS Neurosci Ther. 2011;17(5):271–80.
Zhu M, Lu M, Li QJ, Zhang Z, Wu ZZ, Li J, Qian L, Xu Y, Wang ZY. Hyperbaric oxygen suppresses hypoxic-ischemic brain damage in newborn rats. J Child Neurol. 2015;30(1):75–82.
Yang L, Hei MY, Dai JJ, Hu N, Xiang XY. Effect of hyperbaric oxygenation on mitochondrial function of neuronal cells in the cortex of neonatal rats after hypoxic-ischemic brain damage. Braz J Med Biol Res. 2016;49(5):e5187.
Young GB, Gilbert JJ, Zochodne DW. The significance of myoclonic status epilepticus in postanoxic coma. Neurology. 1990;40(12):1843–8.
Zamponi N, Rychlicki F, Corpaci L, Cesaroni E, Trignani R. Vagus nerve stimulation (VNS) is effective in treating catastrophic 1 epilepsy in very young children. Neurosurg Rev. 2008;31(3):291–7.
Seder DB, Sunde K, Rubertsson S, Mooney M, Stammet P, Riker RR, Kern KB, Unger B, Cronberg T, Dziodzio J, et al. Neurologic outcomes and postresuscitation care of patients with myoclonus following cardiac arrest. Crit Care Med. 2015;43(5):965–72.
Wijdicks EF, Young GB. Myoclonus status in comatose patients after cardiac arrest. Lancet. 1994;343(8913):1642–3.
Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27–34.
Rossetti AO, Logroscino G, Liaudet L, Ruffieux C, Ribordy V, Schaller MD, Despland PA, Oddo M. Status epilepticus: an independent outcome predictor after cerebral anoxia. Neurology. 2007;69(3):255–60.
Yuasa T, Fujita K. Limbic encephalitis—history, symptoms, and the latest classification. Brain Nerve. 2010;62(8):817–26.
Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA a receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13(3):276–86.
Gagnon MM, Savard M, Mourabit AK. Refractory status epilepticus and autoimmune encephalitis with GABAAR and GAD65 antibodies: a case report. Seizure. 2016;37:25–7.
Dalmau J. Status epilepticus due to paraneoplastic and nonparaneoplastic encephalitides. Epilepsia. 2009;50(Suppl 12):58–60.
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, et al. The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging. 2016.
Baysal-Kirac L, Tuzun E, Altindag E, Ekizoglu E, Kinay D, Bilgic B, et al. Are there any specific EEG findings in autoimmune epilepsies? Clin EEG Neurosci. 2016;47(3):224–34.
Cikrikcili U, Ulusoy C, Turan S, Yildiz S, Bilgic B, Hanagasi H, et al. Non-convulsive status epilepticus associated with glutamic acid decarboxylase antibody. Clin EEG Neurosci. 2013;44(3):232–6.
Cyril AC, Nair SS, Mathai A, Kannoth S, Thomas SV. Autoimmune encephalitis: clinical diagnosis versus antibody confirmation. Ann Indian Acad Neurol. 2015;18(4):408–11.
Holzer FJ, Rossetti AO, Heritier-Barras AC, et al. Antibody-mediated status epilepticus: a retrospective multicenter survey. Eur Neurol. 2012;68(5):310–7.
Sarria-Estrada S, Toledo M, Lorenzo-Bosquet C, et al. Neuroimaging in status epilepticus secondary to paraneoplastic autoimmune encephalitis. Clin Radiol. 2014;69(8):795–803.
Rudzinski LA, Pittock SJ, McKeon A, et al. Extratemporal EEG and MRI findings in ANNA-1 (anti-Hu) encephalitis. Epilepsy Res. 2011;95(3):255–62.
Demaerel P, Van Dessel W, Van Paesschen W, et al. Autoimmune-mediated encephalitis. Neuroradiology. 2011;53(11):837–51.
Bellaïche Shavit Y, Graus F, Probst A, et al. Epilepsia partialis continua: a new manifestation of anti-Hu–associated paraneoplastic encephalomyelitis. Ann Neurol. 1999;45(2):255–8.
Drislane FW. Nonconvulsive status epilepticus in patients with cancer. Clin Neurol Neurosurg. 1994;96(4):314–8.
Jacobs DA, Fung KM, Cook NM, et al. Complex partial status epilepticus associated with anti-Hu paraneoplastic syndrome. J Neurol Sci. 2003;213(1):77–82.
Gultekin SH, Rosenfeld MR, Voltz R, et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain. 2000;123(7):1481–94.
Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734–48.
Buckley C, Oger J, Clover L, et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol. 2001;50(1):73–8.
Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia. 2013;54(6):1028–35.
Suleiman J, Brenner T, Gill D, Brilot F, Antony J, Vincent A, et al. VGKC antibodies in pediatric encephalitis presenting with status epilepticus. Neurology. 2011;76(14):1252–5.
Kotsenas AL, Watson RE, Pittock SJ, et al. MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. Am J Neuroradiol. 2014;35(1):84–9.
Ramanathan S, Wong CH, Rahman Z, et al. Myoclonic status epilepticus as a presentation of caspr2 antibody-associated autoimmune encephalitis. Epileptic Disord. 2014;16(4):477–81.
Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7(12):1091–8.
Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–8.
Johnson N, Henry C, Fessler AJ, et al. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology. 2010;75(16):1480–2.
Frisch C, Malter MP, Elger CE, et al. Neuropsychological course of voltage-gated potassium channel and glutamic acid decarboxylase antibody related limbic encephalitis. Eur J Neurol. 2013;20(9):1297–304.
Malter MP, Helmstaedter C, Urbach H, et al. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol. 2010;67(4):470–8.
Vianello M, Tavolato B, Giometto B. Glutamic acid decarboxylase autoantibodies and neurological disorders. Neurol Sci. 2002;23(4):145–51.
Kanter IC, Huttner HB, Staykov D, et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia. 2008;49(5):914–20.
Kumar G, Mittal S, Moudgil SS, et al. Histopathological evidence that hippocampal atrophy following status epilepticus is a result of neuronal necrosis. J Neurol Sci. 2013;334(1):186–91.
Wong SH, Saunders MD, Larner AJ, et al. An effective immunotherapy regimen for VGKC antibody-positive limbic encephalitis. J Neurol Neurosurg Psychiatry. 2010;81(10):1167–9.
Finelli PF. Autoimmune limbic encephalitis with GAD antibodies. Neurohospitalist. 2011;1(4):178–81.
Mazzi G, De Roia D, Cruciatti B, et al. Plasma exchange for anti GAD associated non paraneoplastic limbic encephalitis. Transfus Apher Sci. 2008;39(3):229–33.
Kobayakawa Y, Tateishi T, Kawamura N, et al. A case of immune-mediated encephalopathy showing refractory epilepsy and extensive brain MRI lesions associated with anti-glutamic acid decarboxylase antibody. Clin Neurol. 2010;50(2):92–7.
Korff CM, Parvex P, Cimasoni L, et al. Encephalitis associated with glutamic acid decarboxylase autoantibodies in a child: a treatable condition? Arch Neurol. 2011;68(8):1065–8.
Boronat A, Sabater L, Saiz A, et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76(9):795–800.
Schuler V, Lüscher C, Blanchet C, et al. Epilepsy, hyperalgesia, impaired memory, and loss of pre-and postsynaptic GABA B responses in mice lacking GABA B (1). Neuron. 2001;31(1):47–58.
Lancaster E, Lai M, Hughes E, et al. Autoantibodies to the GABA (B) receptor associate with limbic encephalitis and seizures, and alter GABA (B) receptor function [C]. Neurology. 2010;74(9):A402.
Guan HZ, Ren HT, Yang XZ, et al. Limbic encephalitis associated with anti-γ-aminobutyric acid B receptor antibodies: a case series from China. Chin Med J. 2015;128(22):3023.
Chong JY, Rowland LP, Utiger RD. HE: syndrome or myth? Arch Neurol. 2003;60(2):164–71.
Castillo P, Woodruff B, Caselli R, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis. Arch Neurol. 2006;63(2):197–202.
Monti G, Pugnaghi M, Ariatti A, et al. Non-convulsive status epilepticus of frontal origin as the first manifestation of Hashimoto's encephalopathy. Epileptic Disord. 2011;13(3):253–8.
Jellinek EH, Ball K. Hashimoto's disease and encephalopathy. Lancet. 1966;288(7462):512–4.
Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr. 2013;13(2):62–8.
Park M, et al. Delayed diagnosis of SLE in a patient presenting with intractable status epilepticus. Lupus. 2009;18:474–5.
Fernandez-Torre JL, Sanchez JM, Gonzalez C, et al. Complex partial status epilepticus of extratemporal origin in a patient with systemic lupus erythematosus. Seizure. 2003;12(4):245–8.
Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology. 2004;63(10):1808–12.
Benavente E, Paira S, Roverano S, et al. Encephalitis and status epilepticus in a patient with systemic lupus erythematosus. Reumatol Clín. 2013;9(2):123–7.
Tsuji M, Tanaka H, Yamakawa M, et al. A case of systemic lupus erythematosus with complex partial status epilepticus. Epileptic Disord. 2005;7(3):249–51.
Koppel BS. Connective tissue diseases. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven; 1997. p. 2597–604.
Urbach H, Soeder BM, Jeub M, et al. Serial MRI of limbic encephalitis. Neuroradiology. 2006;48(6):380–6.
Kruer MC, Hoeftberger R, Lim KY, et al. Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of γ-aminobutyric acid type B receptor autoimmunity. JAMA Neurol. 2014;71(5):620–3.
Dhamija R, Renaud DL, Pittock SJ, et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol. 2011;44(4):275–81.
Vincent A. Stiff, twitchy or wobbly—are GAD antibodies pathogenic? Brain. 2008;131(10):2536–7.
Reznik ME, Berger K, Claassen J. Comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus. J Clin Med. 2016;5(5).
Sutter R, Kaplan PW, Rüegg S. Outcome predictors for status epilepticus—what really counts[J]. Nat Rev Neurol. 2013;9(9):525–34.
Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia. 2012;53(s4):127–38.
Shorvon S. Guidelines for status epilepticus: are we there yet? Neurocrit Care. 2012:1–2.
Kirkpatrick MNP, Clarke CD, Sonmezturk HH, et al. Rhythmic delta activity represents a form of nonconvulsive status epilepticus in anti-NMDA receptor antibody encephalitis. Epilepsy Behav. 2011;20(2):392–4.
Chang HR, Kuo CC. Molecular determinants of the anticonvulsant felbamate binding site in the N-methyl-D-aspartate receptor. J Med Chem. 2008;51(6):1534–45.
Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000;39(1):47–55.
Atwater BD, Ai Z, Wolff MR. Fulminant myopericarditis from phenytoin-induced systemic lupus erythematosus. WMJ. 2008;107(6):298–300.
Gunther A, Schubert J, Bramer D, Witte OW. Autoimmune encephalitis. Dtsch Med Wochenschr. 2016;141(17):1244–9.
Sabin TD, Jednacz JA, Staats PN. Case 26-2008: a 26-year-old woman with headache and behavioral changes. N Engl J Med. 2008;359(8):842–53.
Ramanathan S, Mohammad SS, Brilot F, et al. Autoimmune encephalitis: recent updates and emerging challenges. J Clin Neurosci. 2014;21(5):722–30.
Ishiura H, Matsuda S, Higashihara M, et al. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. Neurology. 2008;71:1921–3.
Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDARencephalitis. Neurology. 2011;77:589–93.
Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognositc factorsfor long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–65.
Weimer T, Boling W, Pryputniewicz D, et al. Temporal lobectomy for refractory status epilepticus in a case of limbic encephalitis. J Neurosurg. 2008;109(4):742–5.
Costello DJ, Simon MV, Eskandar EN, et al. Efficacy of surgical treatment of de novo, adult-onset, cryptogenic, refractory focal status epilepticus. Arch Neurol. 2006;63(6):895–901.
Mohamed IS, Otsubo H, Donner E, et al. Magnetoencephalography for surgical treatment of refractory status epilepticus. Acta Neurol Scand. 2007;115(s186):29–36.
Ng Y, Kerrigan JF, Rekate HL. Neurosurgical treatment of status epilepticus. J Neurosurg Pediatr. 2006;105(5):378–81.
Ng Y, Kim HL, Wheless JW. Successful neurosurgical treatment of childhood complex partial status epilepticus with focal resection. Epilepsia. 2003;44(3):468–71.
Correa-Lima AR, de Barros M-FD, Valenca MM, Andrade-Valenca L. Risk factors for acute symptomatic seizure in bacterial meningitis in children. J Child Neurol. 2015;30(9):1182–5.
Annegers JF, Hauser WA, Beghi E, Nicolosi A, Kurland LT. The risk of unprovoked seizures after encephalitis and meningitis. Neurology. 1988;38(9):1407–10.
Prasanth S, Shaji VC, Lyla C, Jayalakshmi V. Refractory status epilepticus due to pneumococcal meningitis in an infant with congenital immunodeficiency. J Pediatr Neurosci. 2016;11(2):125–7.
Singhi SC, Khetarpal R, Baranwal AK, Singhi PD. Intensive care needs of children with acute bacterial meningitis: a developing country perspective. Ann Trop Paediatr. 2004;24(2):133–40.
Wang KW, Chang WN, Chang HW, Chuang YC, Tsai NW, Wang HC, Lu CH. The significance of seizures and other predictive factors during the acute illness for the long-term outcome after bacterial meningitis. Seizure. 2005;14(8):586–92.
Zoons E, Weisfelt M, de Gans J, Spanjaard L, Koelman JH, Reitsma JB, van de Beek D. Seizures in adults with bacterial meningitis. Neurology. 2008;70(22 Pt 2):2109–15.
Maegaki Y, Kurozawa Y, Tamasaki A, Togawa M, Tamura A, Hirao M, Nagao A, Kouda T, Okada T, Hayashibara H, et al. Early predictors of status epilepticus-associated mortality and morbidity in children. Brain Dev. 2015;37(5):478–86.
Chang CJ, Chang HW, Chang WN, Huang LT, Huang SC, Chang YC, Hung PL, Chang CS, Chuang YC, Huang CR, et al. Seizures complicating infantile and childhood bacterial meningitis. Pediatr Neurol. 2004;31(3):165–71.
Wall EC, Cartwright K, Scarborough M, Ajdukiewicz KM, Goodson P, Mwambene J, Zijlstra EE, Gordon SB, French N, Faragher B, et al. High mortality amongst adolescents and adults with bacterial meningitis in sub-Saharan Africa: an analysis of 715 cases from Malawi. PLoS One. 2013;8(7):e69783.
Kim MA, Park KM, Kim SE, Oh MK. Acute symptomatic seizures in CNS infection. Eur J Neurol. 2008;15(1):38–41.
Casado-Flores J, Rodrigo C, Aristegui J, Martinon JM, Fenoll A, Mendez C. Decline in pneumococcal meningitis in Spain after introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2008;27(11):1020–2.
Inoue S, Nakazawa T, Takahashi H, Kaneko K. Seizures in the acute phase of aseptic and bacterial meningitis. No To Hattatsu. 1998;30(6):494–9.
Phillips SA, Shanahan RJ. Etiology and mortality of status epilepticus in children. A recent update. Arch Neurol. 1989;46(1):74–6.
Frenkel AL, Bour F, Plouin P, Jalin C. Prognostic value of EEG in pneumococcal meningitis in children. Rev Electroencephalogr Neurophysiol Clin. 1983;13(1):83–7.
Tuncer O, Caksen H, Arslan S, Atas B, Uner A, Oner AF, Odabas D. Cranial computed tomography in purulent meningitis of childhood. Int J Neurosci. 2004;114(2):167–74.
Lambrechtsen FA, Buchhalter JR. Aborted and refractory status epilepticus in children: a comparative analysis. Epilepsia. 2008;49(4):615–25.
Chaptal J, Passouant P, Brunel D, Latour H, Jean R, Cadilhac J, Carli G. Temporal epilepsy of tuberculous meningitis. Arch Fr Pediatr. 1953;10(4):350–7.
Carletti B, Guareschi A. Aspects of convulsions in sequels of treated tuberculous meningitis. Minerva Pediatr. 1957;9(40):1022–38.
Hacquard M, Henry J, Poire R, Colmart C. Modifications in epilepsy following tuberculous meningitis: electro-clinical & radiological study. Revue Medicale de Nancy. 1958;83:688–95.
Bahemuka M, Murungi JH. Tuberculosis of the nervous system. A clinical, radiological and pathological study of 39 consecutive cases in Riyadh, Saudi Arabia. J Neurol Sci. 1989;90(1):67–76.
Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurol Sci. 2002;23(4):177–82.
Barzegar M, Mahdavi M, Galegolab Behbehani A, Tabrizi A. Refractory convulsive status epilepticus in children: etiology, associated risk factors and outcome. Iran J Child Neurol. 2015;9(4):24–31.
Sinha M, Shafiulla M, Trupti K, Namrata NR, Nadimul H, Sabitha KS, Kumar RV, Jayshree RS. No evidence of association of xenotropic murine leukemia virus-related virus with oral cancers: experience from a tertiary care center in South India. Indian J Cancer. 2015;52(1):61–4.
Pandian JD, Thomas SV, Santoshkumar B, Radhakrishnan K, Sarma PS, Joseph S, Kesavadas C. Epilepsia partialis continua—a clinical and electroencephalography study. Seizure. 2002;11(7):437–41.
Zorn-Olexa C, Laugel V, Martin Ade S, Donato L, Fischbach M. Multiple intracranial tuberculomas associated with partial status epilepticus and refractory infantile spasms. J Child Neurol. 2008;23(4):459–62.
Raut T, Garg RK, Jain A, Verma R, Singh MK, Malhotra HS, Kohli N, Parihar A. Hydrocephalus in tuberculous meningitis: incidence, its predictive factors and impact on the prognosis. J Infect. 2013;66(4):330–7.
Patwari AK, Aneja S, Ravi RN, Singhal PK, Arora SK. Convulsions in tuberculous meningitis. J Trop Pediatr. 1996;42(2):91–7.
Saitoh A, Pong A, Waecker NJ Jr, Leake JA, Nespeca MP, Bradley JS. Prediction of neurologic sequelae in childhood tuberculous meningitis: a review of 20 cases and proposal of a novel scoring system. Pediatr Infect Dis J. 2005;24(3):207–12.
Yaramis A, Gurkan F, Elevli M, Soker M, Haspolat K, Kirbas G, Tas MA. Central nervous system tuberculosis in children: a review of 214 cases. Pediatrics. 1998;102(5):E49.
Sutlas PN, Unal A, Forta H, Senol S, Kirbas D. Tuberculous meningitis in adults: review of 61 cases. Infection. 2003;31(6):387–91.
Arman F, Kaya D, Akgun Y, Kocagoz S. Tuberculous meningitis presenting with nonconvulsive status epilepticus. Epilepsy Behav. 2011;20(1):111–5.
Ranjan P, Kalita J, Misra UK. Serial study of clinical and CT changes in tuberculous meningitis. Neuroradiology. 2003;45(5):277–82.
Rossetti AO, Bromfield EB. Determinants of success in the use of oral levetiracetam in status epilepticus. Epilepsy Behav. 2006;8(3):651–4.
Kalita J, Misra UK, Ranjan P. Predictors of long-term neurological sequelae of tuberculous meningitis: a multivariate analysis. Eur J Neurol. 2007;14(1):33–7.
Mazigo HD, Morona D, Kweka EJ, Waihenya R, Mnyone LL, Heukelbach J. Epilepsy and tropical parasitic infections in sub-Saharan Africa: a review. Tanzan J Health Res. 2013;15(2):102–19.
Crawley J, Smith S, Kirkham F, Muthinji P, Waruiru C, Marsh K. Seizures and status epilepticus in childhood cerebral malaria. QJM. 1996;89(8):591–7.
Newton CR, Kariuki SM. Status epilepticus in sub-Saharan Africa: new findings. Epilepsia. 2013;54(Suppl 6):50–3.
Kariuki SM, Kakooza-Mwesige A, Wagner RG, Chengo E, White S, Kamuyu G, Ngugi AK, Sander JW, Neville BG, Newton CR, et al. Prevalence and factors associated with convulsive status epilepticus in Africans with epilepsy. Neurology. 2015;84(18):1838–45.
Crawley J, Waruiru C, Mithwani S, Mwangi I, Watkins W, Ouma D, Winstanley P, Peto T, Marsh K. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet. 2000;355(9205):701–6.
Ikumi ML, Muchohi SN, Ohuma EO, Kokwaro GO, Newton CR. Response to diazepam in children with malaria-induced seizures. Epilepsy Res. 2008;82(2–3):215–8.
Singh G, Prabhakar S. The effects of antimicrobial and antiepileptic treatment on the outcome of epilepsy associated with central nervous system (CNS) infections. Epilepsia. 2008;49(Suppl 6):42–6.
Medina MT, Aguilar-Estrada RL, Alvarez A, Duron RM, Martinez L, Dubon S, Estrada AL, Zuniga C, Cartagena D, Thompson A, et al. Reduction in rate of epilepsy from neurocysticercosis by community interventions: the Salama, Honduras study. Epilepsia. 2011;52(6):1177–85.
Chuang MJ, Chang WN, Chang HW, Lin WC, Tsai NW, Hsieh MJ, Wang HC, Lu CH. Predictors and long-term outcome of seizures after bacterial brain abscess. J Neurol Neurosurg Psychiatry. 2010;81(8):913–7.
Koszewski W. Epilepsy following brain abscess. The evaluation of possible risk factors with emphasis on new concept of epileptic focus formation. Acta Neurochir. 1991;113(3–4):110–7.
Patel NH, Jain AR, Iyer VK, Shah AG, Jain DA, Shah AA. Clinico—diagnostic and therapeutic relevance of computed tomography scan of brain in children with partial seizures. Ann Indian Acad Neurol. 2013;16(3):352–6.
Intan HI, Zubaidah CD, Norazah A, Norlijah O. Subdural collections due to non-typhi salmonella infections in two Malaysian children. Singap Med J. 2008;49(7):e186–9.
Shimohata M, Naruse S, Kawasaki S, Watanabe Y, Koyama M, Ito Y, Tanaka H. Brain abscess due to fusobacterium necrophorum in a patient with convulsion and no signs of meningitis. Rinsho Shinkeigaku. 2012;52(6):429–32.
Carrasco-Moro R, Garcia-Navarrete E, Pedrosa-Sanchez M, Pascual-Garvi JM, Minervini-Marin M, Sola RG. Refractory epilepsy as the presenting symptom of a brucellar brain abscess. Rev Neurol. 2006;43(12):729–32.
Pitkanen A, Roivainen R, Lukasiuk K. Development of epilepsy after ischaemic stroke. Lancet Neurol. 2015.
Armstrong-Wells J, Ferriero DM. Diagnosis and acute management of perinatal arterial ischemic stroke. Neurol Clin Pract. 2014;4(5):378–85.
Ozdemir HH, Mungen B, Ilhan S. Evaluation of the efficacy of sodium valproate in convulsive status epilepticus following to ischemic stroke. Arq Neuropsiquiatr. 2015;73(4):293–7.
Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43(3 Pt 1):483–8.
Sung CY, Chu NS. Status epilepticus in the elderly: etiology, seizure type and outcome. Acta Neurol Scand. 1989;80(1):51–6.
Koubeissi MZ, Mayor CL, Estephan B, Rashid S, Azar NJ. Efficacy and safety of intravenous lacosamide in refractory nonconvulsive status epilepticus. Acta Neurol Scand. 2011;123(2):142–6.
Kirton A, Armstrong-Wells J, Chang T, Deveber G, Rivkin MJ, Hernandez M, Carpenter J, Yager JY, Lynch JK, Ferriero DM, et al. Symptomatic neonatal arterial ischemic stroke: the International Pediatric Stroke Study. Pediatrics. 2011;128(6):e1402–10.
Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148–52.
Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14(3):348–53.
Rosati A, Ilvento L, L'Erario M, De Masi S, Biggeri A, Fabbro G, Bianchi R, Stoppa F, Fusco L, Pulitano S, et al. Efficacy of ketamine in refractory convulsive status epilepticus in children: a protocol for a sequential design, multicentre, randomised, controlled, open-label, non-profit trial (KETASER01). BMJ Open. 2016;6(6):e011565.
Miras Veiga A, Moreno DC, Menendez AI, Siscart IM, Fernandez MD, Sanchez EG, Gonzalez MG, Saez FG. Effectiveness of electroconvulsive therapy for refractory status epilepticus in febrile infection-related epilepsy syndrome. Neuropediatrics. 2017;48(1):45–8.
Appavu B, Vanatta L, Condie J, Kerrigan JF, Jarrar R. Ketogenic diet treatment for pediatric super-refractory status epilepticus. Seizure. 2016;41:62–5.
Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, Kaplan PW, Geocadin RG, Hartman AL, Venkatesan A, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82(8):665–70.
Yoshimura H, Matsumoto R, Ueda H, Ariyoshi K, Kawamoto M, Ishii J, Ikeda A, Takahashi R, Kohara N. Status epilepticus in the elderly: prognostic implications of rhythmic and periodic patterns in electroencephalography and hyperintensities on diffusion-weighted imaging. J Neurol Sci. 2016;370:284–9.
Canoui-Poitrine F, Bastuji-Garin S, Alonso E, Darcel G, Verstichel P, Caillet P, Paillaud E. Risk and prognostic factors of status epilepticus in the elderly: a case-control study. Epilepsia. 2011;52(10):1849–56.
Kalita J, Nair PP, Misra UK. A clinical, radiological and outcome study of status epilepticus from India. J Neurol. 2010;257(2):224–9.
Nanau RM, Neuman MG. Adverse drug reactions induced by valproic acid. Clin Biochem. 2013;46(15):1323–38.
Labovitz DL, Hauser WA, Sacco RL. Prevalence and predictors of early seizure and status epilepticus after first stroke. Neurology. 2001;57(2):200–6.
Makihara N, Arimura K, Ago T, Tachibana M, Nishimura A, Nakamura K, Matsuo R, Wakisaka Y, Kuroda J, Sugimori H, et al. Involvement of platelet-derived growth factor receptor Beta in fibrosis through extracellular matrix protein production after ischemic stroke. Exp Neurol. 2015;264:127–34.
Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, Zlokovic BV. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron. 2010;68(3):409–27.
So EL, Annegers JF, Hauser WA, O'Brien PC, Whisnant JP. Population-based study of seizure disorders after cerebral infarction. Neurology. 1996;46(2):350–5.
Koubeissi M, Alshekhlee A. In-hospital mortality of generalized convulsive status epilepticus: a large US sample. Neurology. 2007;69(9):886–93.
Sinha S, Satishchandra P, Mahadevan A, Bhimani BC, Kovur JM, Shankar SK. Fatal status epilepticus: a clinico-pathological analysis among 100 patients: from a developing country perspective. Epilepsy Res. 2010;91(2–3):193–204.
Jeon SB, Parikh G, Choi HA, Lee K, Lee JH, Schmidt JM, Badjatia N, Mayer SA, Claassen J. Acute cerebral microbleeds in refractory status epilepticus. Epilepsia. 2013;54(5):e66–8.
Liberalesso PB, Garzon E, Yacubian EM, Sakamoto AC. Higher mortality rate is associated with advanced age and periodic lateralized epileptiform discharges in patients with refractory status epilepticus. Arq Neuropsiquiatr. 2013;71(3):153–8.
Albers JM, Moddel G, Dittrich R, Steidl C, Suntrup S, Ringelstein EB, Dziewas R. Intravenous lacosamide—an effective add-on treatment of refractory status epilepticus. Seizure. 2011;20(5):428–30.
Kang X, Jiang H, Wu C, Liu X, Qiang J, Liu F, Guo Y, Xiao D, Liu J, Yu J, et al. Application of continuous video-electroencephalographic monitoring in patients with consciousness disorders in intensive care unit. Zhonghua Yi Xue Za Zhi. 2015;95(21):1663–6.
Kennel C, Michas-Martin A, Berman BD, Poisson S. Non convulsive status epilepticus masquerading as stroke. Am J Emerg Med. 2015;33(3):482.e1–2.
Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98(2–3):232–7.
Drislane FW, Blum AS, Lopez MR, Gautam S, Schomer DL. Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia. 2009;50(6):1566–71.
Privitera M, Hoffman M, Moore JL, Jester D. EEG detection of nontonic-clonic status epilepticus in patients with altered consciousness. Epilepsy Res. 1994;18(2):155–66.
Tasker RC, Goodkin HP, Sanchez Fernandez I, Chapman KE, Abend NS, Arya R, Brenton JN, Carpenter JL, Gaillard WD, Glauser TA, et al. Refractory status epilepticus in children: intention to treat with continuous infusions of midazolam and pentobarbital. Pediatr Crit Care Med. 2016;17(10):968–75.
Fernandez-Torre JL, Burgueno P, Ballesteros MA, Hernandez-Hernandez MA, Villagra-Teran N, de Lucas EM. Super-refractory nonconvulsive status epilepticus secondary to fat embolism: a clinical, electrophysiological, and pathological study. Epilepsy Behav. 2015;49:184–8.
Legros B, Depondt C, Levy-Nogueira M, Ligot N, Mavroudakis N, Naeije G, Gaspard N. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care. 2014;20(3):484–8.
Belcastro V, Vidale S, Pierguidi L, Sironi L, Tancredi L, Striano P, Taborelli A, Arnaboldi M. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: a proof-of-concept, observational study. Seizure. 2013;22(10):905–7.
Alexopoulos A, Lachhwani DK, Gupta A, Kotagal P, Harrison AM, Bingaman W, Wyllie E. Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis. Neurology. 2005;64(3):567–70.
Atkinson M, Atkinson B, Norris G, Shah A. Refractory status epilepticus secondary to CNS vasculitis, a role for epilepsy surgery. J Neurol Sci. 2012;315(1–2):156–9.
Miras Veiga A, Moreno DC, Menendez AI, Siscart IM, Fernandez MD, Sanchez EG, Gonzalez MG, Saez FG. Effectiveness of electroconvulsive therapy for refractory status epilepticus in febrile infection-related epilepsy syndrome. Neuropediatrics. 2016.
Chiusolo F, Diamanti A, Bianchi R, Fusco L, Elia M, Capriati T, Vigevano F, Picardo S. From intravenous to enteral ketogenic diet in PICU: a potential treatment strategy for refractory status epilepticus. Eur J Paediatr Neurol. 2016;20(6):843–7.
Farias-Moeller R, Bartolini L, Pasupuleti A, Brittany Cines RD, Kao A, Carpenter JL. A practical approach to ketogenic diet in the pediatric intensive care unit for super-refractory status epilepticus. Neurocrit Care. 2017;26(2):267–72.
Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260(2):421–8.
Khoujah D, Abraham MK. Status epilepticus: what’s new? Emerg Med Clin North Am. 2016;34(4):759–76.
Capizzi G, Vittorini R, Torta F, Davico C, Raino E, Conio A, Longobardo A, Briatore E, Podesta B, Calzolari S. Lidocaine treatment in refractory status epilepticus resulting from febrile infection-related epilepsy syndrome: a case report and follow-up. Neuropediatrics. 2015;46(1):65–8.
Tunkel AR, Glaser CA, Bloch KC, Sejvar JJ, Marra CM, Roos KL, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303–27. doi:10.1086/589747.
Venkatesan A, Tunkel AR, Bloch KC, Lauring AS, Sejvar J, Bitnun A, et al. Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis. 2013;57(8):1114–28. doi:10.1093/cid/cit458.
Janz D, Kautz G. Etiology and therapy of status epilepticus. Dtsch Med Wochenschr. 1963;88:2189–94. doi:10.1055/s-0028-1112345.
Resnick J. Pre-eruptive varicella encephalitis presenting as status epilepticus. Minn Med. 1970;53(1):65–7.
Hayakawa T, Sato J, Hara H, Murakami F, Goto T, Fukuyama Y. Therapy and prognosis of status convulsivus in childhood. Folia Psychiatr Neurol Jpn. 1979;33(3):445–56.
Uldry PA, Bernasconi A, Despland PA. Fatal status epilepticus in the course of HIV encephalitis. Presse Med. 1991;20(43):2216–8.
Vooturi S, Jayalakshmi S, Sahu S, Mohandas S. Prognosis and predictors of outcome of refractory generalized convulsive status epilepticus in adults treated in neurointensive care unit. Clin Neurol Neurosurg. 2014;126:7–10. doi:10.1016/j.clineuro.2014.07.038.
Misra UK, Kalita J, Nair PP. Status epilepticus in central nervous system infections: an experience from a developing country. Am J Med. 2008;121(7):618–23. doi:10.1016/j.amjmed.2008.02.012.
Kalita J, Nair PP, Misra UK. Status epilepticus in encephalitis: a study of clinical findings, magnetic resonance imaging, and response to antiepileptic drugs. J Neurovirol. 2008;14(5):412–7. doi:10.1080/13550280802266523.
Sonneville R, Mariotte E, Neuville M, Minaud S, Magalhaes E, Ruckly S, et al. Early-onset status epilepticus in patients with acute encephalitis. Medicine. 2016;95(30):e4092. doi:10.1097/MD.0000000000004092.
Glaser CA, Gilliam S, Honarmand S, Tureen JH, Lowenstein DH, Anderson LJ, et al. Refractory status epilepticus in suspect encephalitis. Neurocrit Care. 2008;9(1):74–82. doi:10.1007/s12028-007-9042-y. Epub 2007/12/22.
Lin JJ, Lin KL, Wang HS, Hsia SH, Wu CT. Analysis of status epilepticus related presumed encephalitis in children. Eur J Paediatr Neurol. 2008;12(1):32–7. doi:10.1016/j.ejpn.2007.05.007. Epub 2007/06/23.
Lin JJ, Lin KL, Hsia SH, Wu CT, Chou IJ, Wang HS. Analysis of status epilepticus with Mycoplasma pneumoniae encephalitis. Pediatr Neurol. 2010;43(1):41–5. doi:10.1016/j.pediatrneurol.2010.02.017.
Vehapoglu A, Turel O, Uygur Sahin T, Kutlu NO, Iscan A. Clinical significance of human metapneumovirus in refractory status epilepticus and encephalitis: case report and review of the literature. Case Rep Neurol Med. 2015;2015:131780. doi: 10.1155/2015/131780. Epub 2015/12/15.
Greco F, Cocuzza MD, Smilari P, Sorge G, Pavone L. Nonconvulsive status epilepticus complicating epstein-barr virus encephalitis in a child. Case Rep Pediatrics. 2014;2014:547396. doi:10.1155/2014/547396.
Bick SK, Izzy S, Rubin DB, Zafar SF, Rosenthal ES, Eskandar EN. Anterior temporal lobectomy for refractory status epilepticus in herpes simplex encephalitis. Neurocrit Care. 2016. doi: 10.1007/s12028-016-0302-6. Epub 2016/07/31.
Kramer AH, Jette N, Pillay N, Federico P, Zygun DA. Epileptiform activity in neurocritical care patients. Can J Neurol Sci. 2012;39(3):328–37.
Carrera E, Claassen J, Oddo M, Emerson RG, Mayer SA, Hirsch LJ. Continuous electroencephalographic monitoring in critically ill patients with central nervous system infections. Arch Neurol. 2008;65(12):1612–8. doi:10.1001/archneur.65.12.1612.
Rautonen J, Koskiniemi M, Vaheri A. Prognostic factors in childhood acute encephalitis. Pediatr Infect Dis J. 1991;10(6):441–6.
Panagariya A, Jain RS, Gupta S, Garg A, Sureka RK, Mathur V. Herpes simplex encephalitis in North West India. Neurol India. 2001;49(4):360–5.
Misra UK, Kalita J. Seizures in encephalitis: predictors and outcome. Seizure. 2009;18(8):583–7. doi:10.1016/j.seizure.2009.06.003.
Armangue T, Moris G, Cantarin-Extremera V, Conde CE, Rostasy K, Erro ME, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85(20):1736–43. doi:10.1212/WNL.0000000000002125.
Gunduz A, Beskardes AF, Kutlu A, Ozkara C, Karaagac N, Yeni SN. Herpes encephalitis as a cause of nonconvulsive status epilepticus. Epileptic Disord. 2006;8(1):57–60.
Lee JH, Nam DH, Oh SY, Shin BS, Seo MW, Jeong SK, et al. Nonconvulsive status epilepticus presenting as epileptic nystagmus in a patient with herpes encephalitis. J Neuroophthalmol. 2012;32(3):249–51. doi:10.1097/WNO.0b013e3182413679.
Sutter R, Kaplan PW, Cervenka MC, Thakur KT, Asemota AO, Venkatesan A, et al. Electroencephalography for diagnosis and prognosis of acute encephalitis. Clin Neurophysiol. 2015;126(8):1524–31. doi:10.1016/j.clinph.2014.11.006.
Ch'ien LT, Boehm RM, Robinson H, Liu C, Frenkel LD. Characteristic early electroencephalographic changes in herpes simplex encephalitis. Arch Neurol. 1977;34(6):361–4.
Bradshaw MJ, Venkatesan A. Herpes simplex virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics. 2016;13(3):493–508. doi:10.1007/s13311-016-0433-7.
Misra UK, Kalita J. Seizures in Japanese encephalitis. J Neurol Sci. 2001;190(1–2):57–60.
van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7(6):719–24. doi:10.1038/89098.
Arnold JC, Singh KK, Milder E, Spector SA, Sawyer MH, Gavali S, et al. Human metapneumovirus associated with central nervous system infection in children. Pediatr Infect Dis J. 2009;28(12):1057–60. doi:10.1097/INF.0b013e3181acd221.
Sanchez Fernandez I, Rebollo Polo M, Munoz-Almagro C, Monfort Carretero L, Fernandez Urena S, Rueda Munoz A, et al. Human metapneumovirus in the cerebrospinal fluid of a patient with acute encephalitis. Arch Neurol. 2012;69(5):649–52. doi:10.1001/archneurol.2011.1094.
Webster DL, Gardner AH, Dye TJ, Chima RS. Status epilepticus: a possible association with human metapneumovirus infection. Pediatrics. 2014;133(3):e747–50. doi:10.1542/peds.2013-0929.
Niizuma T, Okumura A, Kinoshita K, Shimizu T. Acute encephalopathy associated with human metapneumovirus infection. Jpn J Infect Dis. 2014;67(3):213–5.
Schildgen O, Glatzel T, Geikowski T, Scheibner B, Matz B, Bindl L, et al. Human metapneumovirus RNA in encephalitis patient. Emerg Infect Dis. 2005;11(3):467–70.
Kaida A, Iritani N, Kubo H, Shiomi M, Kohdera U, Murakami T. Seasonal distribution and phylogenetic analysis of human metapneumovirus among children in Osaka City, Japan. J Clin Virol. 2006;35(4):394–9. doi:10.1016/j.jcv.2005.12.009.
Hata M, Ito M, Kiyosawa S, Kimpara Y, Tanaka S, Yamashita T, et al. A fatal case of encephalopathy possibly associated with human metapneumovirus infection. Jpn J Infect Dis. 2007;60(5):328–9.
Klein C, Kimiagar I, Pollak L, Gandelman-Marton R, Itzhaki A, Milo R, et al. Neurological features of West Nile virus infection during the 2000 outbreak in a regional hospital in Israel. J Neurol Sci. 2002;200(1–2):63–6.
Nash D, Mostashari F, Fine A, Miller J, O’Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807–14. doi:10.1056/NEJM200106143442401.
Chowers MY, Lang R, Nassar F, Ben-David D, Giladi M, Rubinshtein E, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis. 2001;7(4):675–8. doi:10.3201/eid0704.010414.
Gandelman-Marton R, Kimiagar I, Itzhaki A, Klein C, Theitler J, Rabey JM. Electroencephalography findings in adult patients with West Nile virus-associated meningitis and meningoencephalitis. Clin Infect Dis. 2003;37(11):1573–8. doi:10.1086/379516.
Feki I, Marrakchi C, Ben Hmida M, Belahsen F, Ben Jemaa M, Maaloul I, et al. Epidemic West Nile virus encephalitis in Tunisia. Neuroepidemiology. 2005;24(1–2):1–7. doi:10.1159/000081042.
Bagic A, Boudreau EA, Greenfield J, Sato S. Electro-clinical evolution of refractory non-convulsive status epilepticus caused by West Nile virus encephalitis. Epileptic Disord. 2007;9(1):98–103. doi:10.1684/epd.2007.0056. Epub 2007/02/20.
Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet. 2001;358(9283):729–30. doi:10.1016/S0140-6736(01)05905-0.
Palermo CI, Costanzo CM, Franchina C, Castiglione G, Giuliano L, Russo R, et al. Focal epilepsy as a long term sequela of parvovirus B19 encephalitis. J Clin Virol. 2016;80:20–3. doi:10.1016/j.jcv.2016.04.007.
Skaff PT, Labiner DM. Status epilepticus due to human parvovirus B19 encephalitis in an immunocompetent adult. Neurology. 2001;57(7):1336–7.
Erol I, Alehan F, Yalcin K. Refractory status epilepticus owing to human parvovirus B19 encephalitis in a child. J Child Neurol. 2006;21(9):820–2. Epub 2006/09/15.
Mazur-Melewska K, Brenska I, Jonczyk-Potoczna K, Kemnitz P, Pieczonka-Ruszkowska I, Mania A, et al. Neurologic complications caused by Epstein-Barr virus in pediatric patients. J Child Neurol. 2016;31(6):700–8. doi:10.1177/0883073815613563.
Majid A, Galetta SL, Sweeney CJ, Robinson C, Mahalingam R, Smith J, et al. Epstein-Barr virus myeloradiculitis and encephalomyeloradiculitis. Brain. 2002;125(Pt 1):159–65.
Johkura K, Momoo T, Kuroiwa Y. Thalamic involvement of Epstein-Barr virus encephalitis demonstrated by MRI. J Neurol. 2003;250(3):357–8.
Delgado S, Duran MI. Encephalitis in a renal transplantation patient. Nefrologia. 2004;24(Suppl 3):21–5.
Nishie M, Ogawa M, Kurahashi K. Epstein-Barr virus-associated encephalitis presenting as refractory status epilepticus that persisted for nearly 2 months with excellent recovery. Rinsho Shinkeigaku. 2003;43(7):422–6. Epub 2003/10/30.
Armengol CE, Hendley JO. Cat-scratch disease encephalopathy: a cause of status epilepticus in school-aged children. J Pediatr. 1999;134(5):635–8.
Lewis DW, Tucker SH. Central nervous system involvement in cat scratch disease. Pediatrics. 1986;77(5):714–21.
Singhal AB, Newstein MC, Budzik R, Cha JH, Rordorf G, Buonanno FS, et al. Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathy. J Neuroimaging. 2003;13(1):79–82. Epub 2003/02/21.
Laswell EM, Chambers KD, Whitsel DR, Poudel K. New-onset refractory status epilepticus in an adult with an atypical presentation of cat-scratch disease: successful treatment with high-dose corticosteroids. Pharmacotherapy. 2015;35(6):e106–10. doi:10.1002/phar.1595.
Hildebrand J, Lecaille C, Perennes J, Delattre JY. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology. 2005;65(2):212–5.
Michelucci R, Pasini E, Meletti S, Fallica E, Rizzi R, Florindo I, Chiari A, Monetti C, Cremonini AM, Forlivesi S, et al. Epilepsy in primary cerebral tumors: the characteristics of epilepsy at the onset (results from the PERNO study—project of Emilia Romagna region on neuro-oncology). Epilepsia. 2013;54(Suppl 7):86–91.
Cowie CJ, Cunningham MO. Peritumoral epilepsy: relating form and function for surgical success. Epilepsy Behav. 2014;38:53–61.
Nowell M, Miserocchi A, McEvoy AW. Tumors in epilepsy. Semin Neurol. 2015;35(3):209–17.
Lhatoo SD, Moghimi N, Schuele S. Tumor-related epilepsy and epilepsy surgery. Epilepsia. 2013;54(Suppl 9):1–4.
Japp A, Gielen GH, Becker AJ. Recent aspects of classification and epidemiology of epilepsy-associated tumors. Epilepsia. 2013;54(Suppl 9):5–11.
Lynam LM, Lyons MK, Drazkowski JF, Sirven JI, Noe KH, Zimmerman RS, Wilkens JA. Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg. 2007;109(7):634–8.
Ullrich NJ, Pomeroy SL, Kapur K, Manley PE, Goumnerova LC, Loddenkemper T. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015;56(10):1599–604.
van Breemen MSM, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumors: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6:421–30.
Maschio M. Brain tumor-related epilepsy. Curr Neuropharmacol. 2012;10:124–33.
Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS. Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg. 2008;108:227–35.
Wojcik-Draczkowska H, Mazurkiewicz-Beldzinska M, Mankowska B, Dilling-Ostrowska E. Epileptic seizures as a manifestation of brain tumors: clinical and electroencephalographic correlations. Przegl Lek. 2003;60(Suppl 1):42–4.
Gottschalk J, Korves M, Skotzek-Konrad B, Goebel S, Cervos-Navarro J. Dysembryoplastic neuroepithelial micro-tumor in a 75-year-old patient with long-standing epilepsy. Clin Neuropathol. 1993;12(3):175–8.
Rheims S, Ducray F, Ryvlin P. Choosing the tumoral epilepsy surgery candidate. Epilepsia. 2013;54(Suppl 9):91–6.
van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ. Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol. 2009;256(9):1519–26.
Weller M, Stupp R, Wick W. Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol. 2012;13(9):e375–82.
Weller M, Gorlia T, Cairncross JG, van den Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR, Forsyth P, et al. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology. 2011;77(12):1156–64.
Singh G, Driever PH, Sander JW. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain. 2005;128(Pt 1):7–17.
Glantz MJ, Cole BF, Forsyth PA, Recht LD, Wen PY, Chamberlain MC, Grossman SA, Cairncross JG. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2000;54(10):1886–93.
Kong X, Guan J, Yang Y, Li Y, Ma W, Wang R. A meta-analysis: do prophylactic antiepileptic drugs in patients with brain tumors decrease the incidence of seizures? Clin Neurol Neurosurg. 2015;134:98–103.
Guerrini R, Rosati A, Giordano F, Genitori L, Barba C. The medical and surgical treatment of tumoral seizures: current and future perspectives. Epilepsia. 2013;54(Suppl 9):84–90.
Englot DJ, Berger MS, Barbaro NM, Chang EF. Predictors of seizure freedom after resection of supratentorial low-grade gliomas. A review. J Neurosurg. 2011;115(2):240–4.
Kim SK, Wang KC, Hwang YS, Kim KJ, Chae JH, Kim IO, Cho BK. Epilepsy surgery in children: outcomes and complications. J Neurosurg Pediatr. 2008;1(4):277–83.
Sherman JH, Moldovan K, Yeoh HK, Starke RM, Pouratian N, Shaffrey ME, Schiff D. Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. J Neurosurg. 2011;114(6):1617–21.
Ruda R, Magliola U, Bertero L, Trevisan E, Bosa C, Mantovani C, Ricardi U, Castiglione A, Monagheddu C, Soffietti R. Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro-Oncology. 2013;15(12):1739–49.
Zaatreh MM, Spencer DD, Thompson JL, Blumenfeld H, Novotny EJ, Mattson RH, Spencer SS. Frontal lobe tumoral epilepsy: clinical, neurophysiologic features and predictors of surgical outcome. Epilepsia. 2002;43(7):727–33.
Tiamkao S, Suko P, Mayurasakorn N. Outcome of status epilepticus in Srinagarind hospital. J Med Assoc Thail. 2010;93(4):420–3.
Aladdin Y, Gross DW. Refractory status epilepticus during pregnancy secondary to cavernous angioma. Epilepsia. 2008;49(9):1627–9.
Kasai M, Aoki S, Kobayashi N, Hirahara F, Takahashi T. Status epilepticus due to brain tumor during pregnancy. Clin Case Rep. 2016;4(4):333–5.
Janz D. Status epilepticus and frontal lobe lesions. J Neurol Sci. 1964;1:446–57.
Goonawardena J, Marshman LA, Drummond KJ. Brain tumour-associated status epilepticus. J Clin Neurosci. 2015;22(1):29–34.
Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B. The course of seizure disorders in patients with malignant gliomas. Arch Neurol. 1995;52(7):717–24.
Swisher CB, Doreswamy M, Gingrich KJ, Vredenburgh JJ, Kolls BJ. Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. Neurocrit Care. 2012;16(1):109–13.
Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246–56.
Ng YT, Bristol RE, Schrader DV, Smith KA. The role of neurosurgery in status epilepticus. Neurocrit Care. 2007;7(1):86–91.
Yun C, Xuefeng W. Association between seizures and diabetes mellitus: a comprehensive review of literature. Curr Diabetes Rev. 2013;9(4):350–4.
Moloney TC, Idris I, Waters P, Howell S, Vincent A, Lang B, Maddison P. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study. J Neurol Neurosurg Psychiatry. 2016;87(6):676–7.
Stagg CJ, Lang B, Best JG, McKnight K, Cavey A, Johansen-Berg H, Vincent A, Palace J. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia. 2010;51(9):1898–901.
Vulliemoz S, Seeck M. An association between type 1 diabetes and idiopathic generalized epilepsy. Ann Neurol. 2006;59(4):728.
Kashihara K, Shohmori T, Otsuki S. Noninsulin-dependent diabetes mellitus-related encephalopathy presenting with amnesia, personality change, and autonomic seizure. Intern Med. 1997;36(9):633–6.
Yew TW, McCreight L, Colclough K, Ellard S, Pearson ER. tRNA methyltransferase homologue gene TRMT10A mutation in young adult-onset diabetes with intellectual disability, microcephaly and epilepsy. Diabet Med. 2016;33(9):e21–5.
Zwaveling-Soonawala N, Hagebeuk EE, Slingerland AS, Ris-Stalpers C, Vulsma T, van Trotsenburg AS. Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation. Diabetologia. 2011;54(2):469–71.
Sanyoura M, Woudstra C, Halaby G, Baz P, Senee V, Guillausseau PJ, Zalloua P, Julier C. A novel ALMS1 splice mutation in a non-obese juvenile-onset insulin-dependent syndromic diabetic patient. Eur J Hum Genet. 2014;22(1):140–3.
Poulton CJ, Schot R, Kia SK, Jones M, Verheijen FW, Venselaar H, de Wit MC, de Graaff E, Bertoli-Avella AM, Mancini GM. Microcephaly with simplified gyration, epilepsy, and infantile diabetes linked to inappropriate apoptosis of neural progenitors. Am J Hum Genet. 2011;89(2):265–76.
Huang CW, Tsai JJ, Ou HY, Wang ST, Cheng JT, Wu SN, Huang CC. Diabetic hyperglycemia is associated with the severity of epileptic seizures in adults. Epilepsy Res. 2008;79(1):71–7.
Tsalikian E, Becker DJ, Crumrine PK, Daneman D, Drash AL. Electroencephalographic changes in diabetic ketosis in children with newly and previously diagnosed insulin-dependent diabetes mellitus. J Pediatr. 1981;99(3):355–9.
Burns CM, Rutherford MA, Boardman JP, Cowan FM. Patterns of cerebral injury and neurodevelopmental outcomes after symptomatic neonatal hypoglycemia. Pediatrics. 2008;122(1):65–74.
Cochin JP, Hannequin D, Delangre T, Guegan-Massardier E, Augustin P. Continuous partial epilepsy disclosing diabetes mellitus. Rev Neurol. 1994;150(3):239–41.
Schomer DL. Focal status epilepticus and epilepsia partialis continua in adults and children. Epilepsia. 1993;34(Suppl 1):S29–36.
Makimattila S, Malmberg-Ceder K, Hakkinen AM, Vuori K, Salonen O, Summanen P, Yki-Jarvinen H, Kaste M, Heikkinen S, Lundbom N, et al. Brain metabolic alterations in patients with type 1 diabetes-hyperglycemia-induced injury. J Cereb Blood Flow Metab. 2004;24(12):1393–9.
Tedrus GM, Albertin MC, Odashima NS, Fonseca LC. Partial motor seizures induced by movement in diabetic patients. Arq Neuropsiquiatr. 1991;49(4):442–6.
Caietta E, Halbert C, Lepine A, Khammar A, Cano A, Gavaret M, Mancini J, Villeneuve N, Chabrol B, Simonin G, et al. Association of type 1 diabetes mellitus and epilepsy in children. A cohort of 10 cases. Arch Pediatr. 2012;19(1):9–16.
Fisher BM, Frier BM. Nocturnal convulsions and insulin-induced hypoglycaemia in diabetic patients. Postgrad Med J. 1987;63(742):673–6.
Hennis A, Corbin D, Fraser H. Focal seizures and non-ketotic hyperglycaemia. J Neurol Neurosurg Psychiatry. 1992;55(3):195–7.
El-Hattab AW, Adesina AM, Jones J, Scaglia F. MELAS syndrome: clinical manifestations, pathogenesis, and treatment options. Mol Genet Metab. 2015.
Kim TH, Petrou S, Reid CA. Low glycaemic index diet reduces seizure susceptibility in a syndrome-specific mouse model of generalized epilepsy. Epilepsy Res. 2014;108(1):139–43.
Aylward NM, Shah N, Sellers EA. The ketogenic diet for the treatment of myoclonic astatic epilepsy in a child with type 1 diabetes mellitus. Can J Diabetes. 2014;38(4):223–4.
Roze E, Oubary P, Chedru F. Status-like recurrent pilomotor seizures: case report and review of the literature. J Neurol Neurosurg Psychiatry. 2000;68(5):647–9.
Batista MS, Silva DF, Ferraz HB, de Andrade LA. Complex partial seizures and aphasia as initial manifestations of non-ketotic hyperglycemia. Case report. Arq Neuropsiquiatr. 1998;56(2):296–9.
Eliasson B, Gudbjornsdottir S, Cederholm J, Liang Y, Vercruysse F, Smith U. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial. Int J Obes. 2007;31(7):1140–7.
Baglietto MG, Mancardi MM, Giannattasio A, Minuto N, Rossi A, Capovilla G, Veneselli E, Lorini R, d'Annunzio G. Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep. Neurol Sci. 2009;30(6):509–12.
Paiboonpol S. Epilepsia partialis continua as a manifestation of hyperglycemia. J Med Assoc Thail. 2005;88(6):759–62.
Mukherjee V, Mukherjee A, Mukherjee A, Halder A. Type I diabetes mellitus in a child presenting with epilepsy partialis continua. J Indian Med Assoc. 2007;105(6):340. 342
Mikdashi J, Krumholz A, Handwerger B. Factors at diagnosis predict subsequent occurrence of seizures in systemic lupus erythematosus. Neurology. 2005;64(12):2102–7.
Ramsey-Goldman R, Alarcon GS, McGwin G, Petri M, Vila LM, Edberg JC, et al. Time to seizure occurrence and damage in PROFILE, a multi-ethnic systemic lupus erythematosus cohort. Lupus. 2008;17(3):177–84.
Tsai JD, Lin CL, Lin CC, Sung FC, Lue KH. Risk of epilepsy in patients with systemic lupus erythematosus—a retrospective cohort study. Neuropsychiatr Dis Treat. 2014;10:1635–43.
Brey RL, Holliday SL, Saklad AR, Navarrete MG, Hermosillo-Romo D, Stallworth CL, Valdez CR, Escalante A, del Rincon I, Gronseth G, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology. 2002;58(8):1214–20.
Nasri A, Bedoui I, Mrissa R, Riahi A, Derbali H, Zaouali J, Messelmani M. Mansour M:recurrent status epilepticus in posterior reversible encephalopathy syndrome as initial feature of pediatric lupus: a newly diagnosed case and literature review. Brain Dev. 2016;38:835–41.
Gonzalez-Duarte A, Cantu-Brito CG, Ruano-Calderon L, Garcia-Ramos G. Clinical description of seizures in patients with systemic lupus erythematosus. Eur Neurol. 2008;59(6):320–3.
Mackworth-Young CG, Hughes GR. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry. 1985;48(2):185.
Degirmencioglu H, Sari FN, Alyamac Dizdar E, Say B, Altug N, Uras N, Canpolat FE, Oguz SS. Coexistence of fetal cardiac malformation and maternal drug-induced lupus: is lamotrigine safe? Am J Ther. 2016;23(5):e1263–65.
Leroux G, et al. Posterior reversible encephalopathy syndrome during systemic lupus erythematosus: four new cases and review of the literature. Lupus. 2008:139–47.
Lin SC, Shyur SD, Li Hsin H, Wu JY, Ma YC. Focal seizures as an unusual presentation of neonatal lupus erythematosus. Asian Pac J Allergy Immunol. 2005;23(1):61–4.
Vincent A, Crino PB. Systemic and neurologic autoimmune disorders associated with seizures or epilepsy. Epilepsia. 2011;52(Suppl 3):12–7.
Ainiala H, Dastidar P, Loukkola J, Lehtimaki T, Korpela M, Peltola J, Hietaharju A. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol. 2005;34(5):376–82.
Jeong HW, Her M, Bae JS, Kim SK, Lee SW, Kim HK, Kim D, Park N, Chung WT, Lee SY, et al. Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. Rheumatol Int. 2015;35(5):861–9.
Hawro T, Bogucki A, Krupinska-Kun M, Maurer M, Wozniacka A. Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-beta2GPI antibodies in patients with systemic lupus erythematosus. PLoS One. 2015;10(3):e0119911.
Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, Jara LJ, Fraga-Mouret A, Miranda-Limon JM, Fuentes de la Mata J, Clark P, Vargas F, Alocer-Varela J. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64(4):620–5.
Popescu A, Kao AH. Neuropsychiatric systemic lupus erythematosus. Curr Neuropharmacol. 2011;9(3):449–57.
Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69(12):2074–82.
Chang RS, Cole AJ. Lamotrigine-induced lupus-like syndrome: a case report and literature review. Am J Ther. 2014;21(3):e85–7.
Pelizza L, De Luca P, La Pesa M, Minervino A. Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed. 2006;77(1):17–9.
Hanly JG, Urowitz MB, Su L, Gordon C, Bae SC, Sanchez-Guerrero J, Romero-Diaz J, Wallace DJ, Clarke AE, Ginzler E, et al. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012;71(9):1502–9.
Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15(4):191–7.
Polychronopoulos P, Giannopoulos G, Litsardopoulos P, Soldatos P, Chroni E. Systemic lupus erythematosus manifested as drug-resistant mesial temporal lobe epilepsy. Neurol Sci. 2016.
Gieron MA, Khoromi S, Campos A. MRI changes in the central nervous system in a child with lupus erythematosus. Pediatr Radiol. 1995;25(3):184–5.
Prabhakar S, Bhatia R. Management of agitation and convulsions in hepatic encephalopathy. Indian J Gastroenterol. 2003;22(Suppl 2):S54–8.
Ardizzone G, Arrigo A, Schellino MM, Stratta C, Valzan S, Skurzak S, Andruetto P, Panio A, Ballaris MA, Lavezzo B, et al. Neurological complications of liver cirrhosis and orthotopic liver transplant. Transplant Proc. 2006;38(3):789–92.
Tanaka H, Ueda H, Kida Y, Hamagami H, Tsuji T, Ichinose M. Hepatic encephalopathy with status epileptics: a case report. World J Gastroenterol. 2006;12(11):1793–4.
Kumar R, Shalimar, Sharma H, Prakash S, Panda SK, Khanal S, Acharya SK. Persistent hyperammonemia is associated with complications and poor outcomes in patients with acute liver failure. Clin Gastroenterol Hepatol. 2012;10(8):925–31.
Rama Rao KV, Jayakumar AR, Norenberg MD. Glutamine in the pathogenesis of acute hepatic encephalopathy. Neurochem Int. 2012;61(4):575–80.
Derle E, Kibaroglu S, Ocal R, Kirnap M, Kilinc M, Benli S, Haberal M. Seizure as a neurologic complication after liver transplant. Exp Clin Transplant. 2015;13(Suppl 1):323–6.
Ghosh PS, Hupertz V, Ghosh D. Neurological complications following pediatric liver transplant. J Pediatr Gastroenterol Nutr. 2012;54(4):540–6.
Thabah MM, Singh KK, Madhavan SM, Gupta R. Adult onset Still’s disease as a cause of acute liver failure. Trop Gastroenterol. 2008;29(1):35–6.
Ferro JM, Viana P, Santos P. Management of neurologic manifestations in patients with liver disease. Curr Treat Options Neurol. 2016;18(8):37.
Lacerda G, Krummel T, Sabourdy C, Ryvlin P, Hirsch E. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology. 2006;67(12 Suppl 4):S28–33.
Asconape JJ. Use of antiepileptic drugs in hepatic and renal disease. Handb Clin Neurol. 2014;119:417–32.
Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure—a controlled clinical trial. J Hepatol. 2004;41(1):89–96.
Eleftheriadis N, Fourla E, Eleftheriadis D, Karlovasitou A. Status epilepticus as a manifestation of hepatic encephalopathy. Acta Neurol Scand. 2003;107(2):142–4.
Jo YM, Lee SW, Han SY, Baek YH, Ahn JH, Choi WJ, Lee JY, Kim SH, Yoon BA. Nonconvulsive status epilepticus disguising as hepatic encephalopathy. World J Gastroenterol. 2015;21(16):5105–9.
Scorza FA, Albuquerque M, Arida RM, et al. Seizure occurrence in patients with chronic renal insufficiency in regular hemodialysis program. Arq Neuropsiquiatr. 2005;63:757–60.
Rufo Campos M, Vazquez Florido AM, Madruga Garrido M, Fijo J, Sanchez Moreno A, Martin Govantes J. Renal failure as a factor leading to epileptic seizures. An Esp Pediatr. 2002;56(3):212–8.
Cassinotto C, Mejdoubi M, Signate A, Herbland A, Olindo S, Deramond H. MRI findings in star-fruit intoxication. J Neuroradiol. 2008;35(4):217–23.
Soliman AR, Helmy S. Status epilepticus induced by putrid salted gray mullet fish intoxication in patients with chronic kidney disease. Hemodial Int. 2010;14(4):523–5.
Kao LW, Nanagas KA. Carbon monoxide poisoning. Emerg Med Clin North Am. 2004;22(4):985–1018.
Abdulaziz S, Dabbagh O, Arabi Y, Kojan S, Hassan I. Status epilepticus and cardiopulmonary arrest in a patient with carbon monoxide poisoning with full recovery after using a neuroprotective strategy: a case report. J Med Case Rep. 2012;6:421.
Wong M, Mallory GB Jr, Goldstein J, Goyal M, Yamada KA. Neurologic complications of pediatric lung transplantation. Neurology. 1999;53(7):1542–9.
Laaban JP, Marsal L, Waked M, Vuong TK, Rochemaure J. Seizures related to severe hypophosphataemia induced by mechanical ventilation. Intensive Care Med. 1990;16(2):135–6.
Zhang YX, Liu JR, Jiang B, Liu HQ, Ding MP, Song SJ, Zhang BR, Zhang H, Xu B, Chen HH, et al. Lance-Adams syndrome: a report of two cases. J Zhejiang Univ Sci B. 2007;8(10):715–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Wang, X., Zhang, Y., Leung, H. (2017). Clinical Features of Refractory Status Epilepticus in Various Conditions. In: Wang, X., Li, S. (eds) Refractory Status Epilepticus. Springer, Singapore. https://doi.org/10.1007/978-981-10-5125-8_4
Download citation
DOI: https://doi.org/10.1007/978-981-10-5125-8_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-5124-1
Online ISBN: 978-981-10-5125-8
eBook Packages: MedicineMedicine (R0)